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 There is an increase in prevalence of peanut allergy, especially in the western 
world. The only current treatment for peanut allergy is avoidance of peanut from diet and 
contact. Additionally, there is currently no specific vaccine that can be taken to decrease 
peanut allergies. The method of desensitizing a person allergic to peanut allergy is deemed 
unsafe as the smallest amount of peanut can trigger an anaphylaxis reaction. Thus, various 
allergoids were created by modifying major peanut protein allergen Ara h2 using various 
cross-linkers and modification agents in order to disrupt the binding surface epitopes of the 
antigen to antibody.  
Diabetes is also a growing problem that affects millions of people globally. Having 
diabetes is known to lead to various morbidity as well which can be detrimental to the 
patient and a burden to the economy. Various drugs are available as monotherapy for 
diabetes; however, we aimed to develop dual acting compounds that would not only control 
type 2 diabetes but also commonly associated diagnosis of hypertension as well. Thus, we 
have successfully synthesized and tested compounds in vitro as effective dipeptidyl 
peptidase-IV (DPP-IV) inhibitors and potentially effective in treating hypertension (future 
study) associate with diabetes by utilizing cyanopyrrolidines and β-amino alcohols 




Table of Contents 
Abstract ............................................................................................................................v 
List of Figures ..................................................................................................................ix 
List of Tables ...................................................................................................................xii 
Chapter 1: Understanding Allergens in Peanuts ..............................................................1 
Introduction ................................................................................................................1 
Species of Peanut .................................................................................................1 
Proteins that Elicit Allergic Reaction from Peanuts, Specifically Ara h2 ...........2 
Peanut as an Allergen...........................................................................................8 
Modification of Ara h2 as a Potential Immunotherapy Stimulant .......................13 
Chapter 2: Purification of Ara h2 and Modification with Cross-Linkers ........................17 
Introduction to Cross-Linkers ....................................................................................17 
Research Design and Methods ...................................................................................29 
 Protein Purification Method 1 ..............................................................................29 
 Protein Purification Method 2 ..............................................................................31 
 BS3 Reaction ........................................................................................................33 
 Sulfo-EGS Reaction .............................................................................................35 
 DST Reaction .......................................................................................................36 
 BM(PEG)3 Reaction.............................................................................................37 
 EDC Reaction ......................................................................................................38 
 SDS-PAGE Protocol ............................................................................................39 
Results and Discussion ..............................................................................................39 
NHS Ester Reactions............................................................................................39 
vii 
 
Table of Contents (continued) 
Sulfhydryl Reaction Using Maleimide ................................................................48 
Amide Bond Formation Between Carboxylic Acid and Primary Amine ............50 
Method 1 vs Method 2 .........................................................................................51 
Conclusion .................................................................................................................58 
Chapter 3: Dipeptidyl Peptidase-IV Inhibition for Treatment of Type 2 Diabetes .........60 
Introduction ................................................................................................................60 
Diabetes Mellitus .................................................................................................60 
Important Hormones of Pancreas in Maintaining Homeostasis of Blood 
Glucose ................................................................................................................62 
Importance of Controlling Symptoms Related to Diabetes Mellitus ...................65 
Sulfonylureas and Meglitinides Class of Drugs...................................................69 
Biguanides Class of Drugs ...................................................................................70 
SGLT2 Inhibitor Class of Drugs ..........................................................................70 
Thiazolidinediones Class of Drugs ......................................................................71 
Alpha-Glucosidase Inhibitor Class of Drugs .......................................................72 
GLP-1 Analogs Class of Drugs............................................................................72 
DPP-IV Enzyme Inhibitor Class of Drugs ...........................................................74 
Chapter 4: Characteristic of DPP-IV Inhibitors and their Validation via In Vitro DPP-
IV Enzymatic Assay ........................................................................................................80 
Novel Compounds Containing Cyanopyrrolidine and β-Amino Alcohols 
Scaffolds ....................................................................................................................80 
Research Design and Methods ...................................................................................81 
viii 
 
Table of Contents (continued) 
General Method A: Synthesis of Mono-Alkylated Amino Alcohols...................81 
General Method B. Synthesis of Double-Alkylated Amino Alcohols .................81 
Compounds ..........................................................................................................81 
In Vitro Assay .......................................................................................................83 
Results and Discussion ..............................................................................................84 
Conclusion .................................................................................................................87 
Chapter 5: Summary Remarks .........................................................................................101 
Peanut Allergies .........................................................................................................101 






List of Figures 
Figure Page 
Figure1. Molecular modeling of Ara h2 protein using VMD software ...........................7 
Figure 2. Chemical structures of cross-linkers used to modify Ara h2 ...........................18 
Figure 3. Molecular modeling of Ara h2 showing Lys residues using VMD software ...19 
Figure 4. Reaction schematic of cross-linker BS3 ...........................................................20 
Figure 5. Reaction schematic of cross-linker Sulfo-EGS ................................................22 
Figure 6. Reaction schematic of cross-linker DST ..........................................................23 
Figure 7. Molecular modeling of Ara h2 showing Cys residues using VMD software ...25 
Figure 8. Reaction schematic of cross-linker BM(PEG)3 ................................................26 
Figure 9. Molecular modeling of Ara h2 showing Asp and Glu residues using VMD 
software .............................................................................................................27 
Figure 10. Reaction schematic of cross-linker EDC ........................................................28 
Figure 11. Two-step coupling reaction schematic of EDC and sulfo-NHS .....................29 
Figure 12. SDS-PAGE of BS3 cross-linker in pH 8.........................................................44 
Figure 13. SDS-PAGE of BS3 cross-linker in pH 10.7....................................................45 




List of Figures (continued) 
Figure 15. SDS-PAGE of Sulfo-EGS cross-linker ..........................................................47 
Figure 16. SDS-PAGE of DST cross-linker ....................................................................48 
Figure 17. SDS-PAGE of BM(PEG)3 cross-linker ..........................................................49 
Figure 18. SDS-PAGE of EDC cross-linker ....................................................................50 
Figure 19. SDS-PAGE analysis of different buffers used to extract protein ...................52 
Figure 20. Analysis of fractions at absorbance 595 after Q-Sepharose column 
chromatography .............................................................................................55 
Figure 21. SDS-PAGE of fractions collect after Q-Sepharose column chromatography 
using method 2 ...............................................................................................56 
Figure 22. Flowchart comparison of Method 1 and Method 2 ........................................57 
Figure 23. Molecular modeling of DPP-IV enzyme that is observed as a homodimer ...75 
Figure 24. Molecular modeling of DPP-IV enzyme in complex with inhibitors .............79 
Figure 25. Dose-response curve showing IC50 of compounds 1aa, 1ab, 1ba, and 1bb ....91 
Figure 26. Dose-response curve showing IC50 of compounds 1aa, 2aa, 3aa, and 4aa .....92 
Figure 27. Dose-response curve showing IC50 of compounds 4aa, 4ab, 4ba, and 4bb ....93 
Figure 28. Dose-response curve showing IC50 of compounds 5aa, 5ab, 5ba, and 5bb ....94 
Figure 29. Dose-response curve showing IC50 of compounds 6aa, 6ab, 6ba, and 6bb ....95 
xi 
 
List of Figures (continued) 
Figure 30. Dose-response curve showing IC50 of compounds 7aa, 7ab, 7ba, and 7bb ....96 
Figure 31. Dose-response curve showing IC50 of compounds 8aa, 8ab, 8ba, and 8bb ....97 
Figure 32. Dose-response curve showing IC50 of compounds 9aa, 9ab, 9ba, and 9bb ....98 
Figure 33. Dose-response curve showing IC50 of compounds 10aa, 11aa, and 12aa .......99 

















List of Tables 
Table Page 
Table 1. List of major allergens of peanut and its corresponding protein family name 
and molecular weight as resolved by SDS-PAGE ............................................3 
Table 2. SAR activity of compounds 1 to 9 .....................................................................89 






















Understanding Allergens in Peanuts 
Introduction 
Species of peanut. Peanuts are widely used around the world for their source of 
high quality protein and oil content. World production of peanut is about 30 million metric 
tons per year with China, India and U.S. producing 13.4, 7.7 and 1.8 million metric tons, 
respectively. Just for comparison to see the utilization and importance of peanuts, the 
global corn production in year 2004/2005 was 706 thousand metric tons out of which U.S. 
produced about 300 thousand metric tons of corn. Seven states in the U.S. account for 99 
percent of all peanuts grown. Georgia produces the largest (41%), followed by Texas 
(24%), Alabama (10%), North Carolina (9%), Florida (6%), Virginia (5%) and Oklahoma 
(5%). Peanuts are used as value-added product in numerous applications which include but 
not limited to peanut flour, peanut oil, roasted peanuts and peanut butter.1 Despite such 
high usage of peanuts, the prevalence of peanut allergy is becoming a growing concern in 
the westernized world thus making them an important plant seed of study.2-7  
Peanuts are different from other tree nuts like almonds and walnuts because they 
produce their seeds just below the ground. Peanuts are of the genus Arachia, species 
Arachis hypogaea, which is a member of the legume family (Fabaceae) dating back to 
2000-3000 B.C. in the Peruvian excavations.8 Peanut species A. hypogaea is divided into 
two subspecies, hypogaea (hypogaea hypogaea) and fastigiata (fastigiata vulgaris and 
fastigiata fastigiata), commonly called Virginia, Spanish, and Valencia, respectively. 
There is a hybrid between subspecies of Virginia and Spanish called Runner.9 Runners are 
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the dominant peanut type grown in U.S. (80% of total U.S. production) since they provide 
the most yield and are used to make the most eaten style of peanut in U.S., peanut butter. 
Virginia peanuts (account for about 15% of total U.S. production) have the largest kernels 
and sold predominantly as roasted peanuts in their shells. Spanish peanuts (account for 4% 
of U.S. production) have a smaller kernel with reddish-brown skin with highest oil content 
than other types of peanuts. Valencia peanuts (account for less than one percent U.S. 
production) have three or more small kernels per pod and are very sweet sold in shell, or 
eaten boiled.1  
Although there were numerous different types of species, subspecies and varieties 
of peanut in the beginning and middle of the 20th century, the only cultivars used for 
breeding now are Virginia, Spanish, and Valencia. Runner, although it is a hybrid, is also 
considered a cultivar since it has been in use for a long time.9 Thus, it is important to focus 
on these different varieties as they are the most used around the world. It has been shown 
by Sheppard and Rudolf10 that the four different peanut types have no significant 
differences in fat, ash or protein content. Approximately 90% of total fatty acid content of 
peanut oil is composed of 10% palmitic acid and 80% oleic and linoleic acid. Runner and 
Virginia type showed similar oleic and linoleic acid content than Valencia and Spanish 
subspecies.10 Peanut seeds in general contain about 44-56% oil content and about 24-29% 
protein content across various types of peanuts.9,11 Along with same protein content, the 
amount of protein that is extractable is about the same among different peanut varieties as 
well.9  
Proteins that elicit allergic reaction from peanuts, specifically Ara h2. Since 
mostly proteins are responsible for mediating allergic reaction, it is important to focus on 
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the different types of allergens in the peanut seed. Currently up to date, World Health 
Organization (WHO) and International Union of Immunological Societies (IUIS) Allergen 
Nomenclature Subcommittee have identified 16 different peanut allergens that are capable 
of eliciting allergic reactions with the exception of Ara h4 which is now classified and 
termed as Ara h3.02 under Ara h3 family. The allergens are classified from Ara h1 to Ara 





List of major allergens of peanut and its corresponding protein family name and molecular 
weight as resolved by SDS-PAGE. 
 







The protein super families are cupin (Ara h1, Ara h3, Ara h3.02), the prolamin (Ara 
h2, Ara h6, Ara h7, Ara h9, Ara h16, Ara h17), the profilin (Ara h5), the Bet v 1 (Ara h8), 
the glycosyl transferase GT-C (Ara h10, Ara h11, Ara h14, Ara h15), and the scorpion 
toxin-like knottin (Ara h12, Ara h13).11 Proteins are classified as such due to their 
similarity in structure and sequence to the superfamilies. The cupin allergen Ara h1 is a 
member of vicilins or 7Sglobulins which are characterized as lacking cysteine residues and 
by disk-shaped trimeric proteins whose subunit vary due to posttranslational proteolytic 
processing and glycosylation. The other cupin protein Ara h3 is from legumin or 11S 
globulins family which are hexameric proteins that are linked by a single disulfide bond. 
The prolamin superfamily are characterized by containing eight cysteine residues but have 
very little to none sequence similarity. The 3-dimensional structure consists of bundles of 
four α-helices stabilized by disulfide bonds.11 Other protein superfamilies are important; 
however, the most allergenic groups are cupin and prolamin, specifically allergens Ara h1 
and Ara h2 as described below. 
Out of the 17 different peanut allergens, Ara h1 and Ara h2 have been found to be 
the most potent in eliciting allergic reaction.13,14 The reason they are categorized as a major 
peanut allergen is because they are recognized by greater than ninety percent IgE of peanut 
allergic patients.9,13-15 IgE is short for immunoglobulin E which are responsible for 
protecting the body from foreign substances (talked below in section “peanut as an 
allergen”). Ara h3 is sometimes identified as a major or minor allergen depending on the 
population sample with a range of 44-77% of IgE mediated reaction in peanut allergic 
population.16 Another definition of major peanut allergen is proteins that are responsible 
for a majority of effector activity of food rather than just IgE recognition. Effector activity 
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is referred to the ability of an allergen to effectively cross-link IgE and activate mast cells 
and basophils since this is clinically relevant, and according to this definition, Ara h2 and 
Ara h6 have been found as major peanut allergens in crude peanut extracts.17,18   
Most protein from the peanut seed is stored in the protein superfamilies’ of cupin 
or prolamin of peanut. The cupin Ara h1 was determined by Koppelman et al.9 to be 12-
16% of total protein content and the 2S albumin Ara h2 to be 5.9-9.3% of total protein 
content in peanut. All of the classes combined account for 85% of total peanut protein 
while Ara h1, Ara h2 and Ara h3 together account for 75% of total protein content.11 Study 
by Koppelman et al.9 concluded that differences in serology between peanut allergic 
patients from different parts of the world are not explained by the allergen composition of 
different peanut types. Thus, a focus on the different protein allergens from peanut seed 
are of importance, particularly Ara h2.  
It has been found that Ara h2 has peptide sequences that are similar to peptides in 
Ara h1 and Ara h3, which helps to explain co-sensitization to the three major allergens 
even though the structure, sequence, and protein groups are not similar.19 It has been shown 
that Ara h2 is resistant to further enzymatic fragmentation after treatment with trypsin, 
chymotrypsin, or pepsin. The remaining large fragments are shown to contain intact IgE-
binding epitopes which makes Ara h2 a very potent allergen.20  
 This research is specifically on the protein Ara h2 since it is found to be the most 
potent allergen via IgE recognition and as a major effector activity of peanuts.17,21 Ara h2 
is found to have two classes of protein isoforms (2.01 with 18.0 kDa and 2.02 with 17.7 
kDa) which vary with addition of a 12-residue sequence in the flexible loop region of the 
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protein structure.22,23 Native Ara h2 consists of 31% α-helix, 10% β-strand, and 59% 
random coil and/or loops; roasted Ara h2 consists of 29% α-helix, 12% β-strand, and 59% 
random coil and/or loops.24 Ara h2 is a monomeric protein with 5 helices and 8 cysteine 
residues that form 4 disulfide bonds with at least one disulfide bond connecting each helix 
to another.25 The disulfide bonds are important in stability of the secondary structure and 
maintaining allergenicity. A 3D molecular model of Ara h2 can be seen in Figure 1 that 
was created using VMD software.26 Ara h2 is found to be a weak trypsin inhibitor (trypsin 
binding residues 76 to 85) whose activity is enhanced by 3.5-fold due to roasting. Ara h1 
is known to under go degradation by trypsin, however, Ara h2 being a weak trypsin 
inhibitor, it protects Ara h1 and increases potency of Ara h1 in roasted peanuts.24  
It is important to be able to recognize important IgE-binding epitopes of Ara h2 
since they can further help shed light on the therapeutic approaches to peanut 
hypersensitivity to prevent anaphylaxis and potentially desensitize patients. Ara h2 
contains 157-amino acids and within the protein there are 10 IgE-binding epitopes. Three 
epitopes are found between aa17-39, four epitopes between aa41-80 and three epitopes 
between aa114-157. These 10 IgE-binding epitopes include 63% amino acids that are either 
polar uncharged or apolar residues. Out of the 10 IgE, there are 3 immunodominant IgE at 
aa27-36, aa57-66, and aa65-74. It was shown that even one amino acid modification from 





Figure 1. Molecular modeling of Ara h2 protein using VMD software. Note: non-polar 




Peanut as an allergen. Despite such heavy use of peanuts by the world and a long 
history of cultivation, peanut allergies are on the rise. Research on food allergy has been 
discussed in scientific literature as early as 1912 with the first major peanut allergen to be 
documented and named (Ara h1) in 1991.14,27 Not just peanut allergies but allergies to food 
have been increasing in the westernized countries. Although any food can cause an allergic 
response, the most common are milk, eggs, fish (e.g., bass, flounder, cod), crustacean 
shellfish (e.g., crab, lobster, shrimp), tree nuts (e.g., almonds, walnuts, pecans), peanuts, 
wheat and soybeans. According to the Food Allergen Labeling and Consumer Protection 
Act (FALCPA) of 2004, it is mandated that these eight major allergens be labelled in foods 
that contain these declared major food allergens. These common allergies account for 90% 
of all food allergies.28,29  
According to guidelines for the diagnosis and management of food allergy in the 
U.S., food allergy is defined as “an adverse health effect arising from a specific immune 
response that occurs reproducibly on exposure to a given food.” Immune related food 
allergy can be IgE mediated, non-IgE mediatd, Mixed IgE and non-IgE mediated, or cell 
mediated. Non-immune related adverse reaction to food can be metabolic, pharmacologic, 
toxic or idiopathic/undefined in relation so it is important to properly identify the allergen 
according to guidelines for food allergy management. Foods that do elicit reproducible 
adverse reactions but not linked immunologically are not considered food allergens and 
instead are called food intolerances (e.g. lactose intolerance).2 
Peanut allergy is IgE-mediated and there are two stages in the development of an 
IgE-mediated allergy. Upon first exposure to the allergen, sensitization stage occurs. When 
an allergen is consumed, gastric acid and digestive enzymes break down the protein that 
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are then exposed to mucosal immune system in gastrointestinal tract. This exposure causes 
plasma cells to produce allergen-specific IgE (a-sIgE) to the peptide fragment that was 
exposed on the allergen. This a-sIgE then attaches to mast cells and basophils via FcεRI 
receptors, concluding the first stage.27  
The second stage, allergic reaction, is initiated upon second exposure to peanuts, 
specifically peanut protein and their peptide fragment containing epitopes. These allergens 
then bind to and cross-link two or more IgE-FcεRI complexes that are on the surface of the 
mast cells or basophils resulting in basophil or mast cell degranulation and subsequent 
release of various inflammatory mediators, such as cytokines, chemokines, lipid mediators, 
and histamines. These chemicals cause a series of local symptoms, such as itching, 
swelling, nausea/vomiting, and diarrhea, in addition to various systemic symptoms, such 
as airway obstruction, hives, low blood pressure, and even fatal anaphylaxis.27,30 
The most common types of allergies among children are food or digestive allergies, 
skin allergies such as eczema, and respiratory allergies such as hay fever. There has also 
been an increase in prevalence of skin allergies among children as well. Children with skin 
allergies went from 7.4% in 1997-1999 to 12.5% in 2009-2011. There is no significant 
trend in respiratory allergies from 1997-1999 but from 2009-2011, the prevalence rate has 
been 17%.31 
Although peanuts contain approximately the same protein content across different 
varieties, there is a difference in prevalence of peanut allergies across different parts of the 
world.9 There have been many theories postulating why the prevalence of peanut allergy is 
increasing in the western world over the last decade. The theories include; imbalance 
10 
 
between the T-helper 1 (Th1)/T-helper 2 (H2)-biased cellular responses in early life, 
exposure of peanut allergens in breast milk of lactating women sensitizing the infant,32 
preparation of peanut (dry roasting in U.S. and other western countries), family history of 
peanut allergy, consumption of soy during infancy along with onset of skin allergies and 
exposure to topical preparations (e.g. treatment for anti-rash, eczema, dry skin, etc.) 
containing peanut oil.2,24,29 On the contrary, it has been shown by Du Toit et al.6 through 
their Learning Early about Peanut Allergy (LEAP) trial that early introduction of peanuts 
significantly decreased the frequency of the development of peanut allergy among children 
at high risk for this allergy and modulated immune responses to peanuts. 
One study by Du Toit et al.33 was able to show that early introduction of peanut in 
infants’ diet relates to a decrease and ultimately prevention of development of peanut 
allergy. They studied prevalence of Jewish children living in UK and living in Israel. The 
reason for this group of children that were studied was that children in Israel were fed 
peanut within the first year of their life and children in UK had avoidance of peanut till 
later age. The results showed a 10-fold higher prevalence of peanut allergies in Jewish 
children living in UK versus Jewish children in Israel.33 This goes to show that the 
guidelines recommending avoidance of peanuts during infancy is rather incorrect and that 
actually an early exposure is better to preventing peanut allergies.6  
Unfortunately, the current treatment for food allergy is avoidance of that food 
allergen. In an incidence of accidental ingestion of allergen, prompt administration of 
epinephrine is recommended to treat anaphylactic reaction.2 Peanuts and other tree nuts 
have shown to be persistent allergen with lowest amount of resolution as the children ages 
among the common allergens. Study by Skolnick et al.34 demonstrates that about 21.5% of 
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children outgrown their peanut allergy and that children with low peanut IgE levels should 
be offered a peanut challenge in a medical setting to demonstrate if they can now tolerate 
peanuts. For comparison, children with allergies to egg and milk is resolved by 11% and 
19%, respectively, by age 4 years and that about 80% of these allergies are resolved by age 
16 years.5 Due to consistency of peanut allergies in children and as adults, it is of the most 
important allergy to be studied and focused on. 
The average number of food related incidence per year in the U.S. shows 125,000 
emergency department visits and 53,700 episodes of anaphylaxis.5 Food-induced 
anaphylaxis occurred every 5 minutes in the U.S. between years 2001 and 2005 with nearly 
one-half million emergency department visits.35 The annual incidence rate of children with 
food allergy is at 14.3% and surprisingly 85% of these children attended schools 
prohibiting peanuts.36 Food allergies are an important concern for U.S. as they impact the 
economy. The overall economic cost of food allergy was estimated at $24.8 billion 
annually, which is about $4184 per year per child. Direct medical costs are estimated to be 
$4.3 billion annually, costs borne by the family totaled $20.5 billion annually, lost labor 
productivity costs totaled $0.77 billion annually, out-of-pocket costs totaled $5.5 billion 
annually and opportunity costs totaled $14.2 billion annually. The caregivers reported a 
willingness to pay $20.8 billion annually which is $3504 per year per child for food allergy 
treatment.37 Clearly, there is a significant medical cost to having food allergy that is bared 
by the U.S. health care system and even more so by families with a food allergic child. 
The adverse immune responses to foods affect approximately 15 million people.4,38 
Out of the 15 million people, an estimated 9 million or 3-4% are adults who have food 
allergies.5 A 2008 CDC prevention report indicated an 18% increase in children food 
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allergy from year 1997 to 2007, with an estimated 3.9% of children currently affected. 
Specifically, for peanut allergy in the U.K. and U.S., the prevalence rates have essentially 
doubled for children exceeding 1%.5 Looking at 11-year follow-up study by Sicherer et al.7 
showed prevalence of peanut allergy in children in 2008 to be 1.4% compared with 0.8% 
in 2002 and 0.4% in 1997. 
However, a more recent study completed by Gupta et al.38 suggests that the 
prevalence and severity of childhood food allergy is greater than in previously reported 
studies. Gupta et al.38 suggests that food allergy prevalence is actually 8.0% rather than 
3.9% in children, which is nearly 5.9 million affected children in U.S. With no surprise, 
the prevalence among all children (without food allergy) surveyed for all ages showed 
peanuts (2.0%) to be the highest prevalence frequency followed by milk (1.7%), shellfish 
(1.4%), tree nut (1.0%), egg (0.8%), fin fish (0.5%), wheat (0.4%) and soy (0.4%). 
Prevalence among children (with food allergy) surveyed showed peanuts (25.2%) to be the 
highest followed by milk (21.1%), shellfish (17.2%), tree nut (13.1%), egg (9.8%), fin fish 
(6.8%), wheat (5.0%) and soy (4.6%).38  
Gupta et al.38 also conducted a study to evaluate the history of severity of common 
food allergies among affected children. Severe reaction was seen in 38.7% of affected 
children and mild-to-moderate reaction in 61.3% of affected children. Children who had 
multiple food allergies accounted for 2.4% of all children corresponding to 30.4% of 
children with food allergy. Needing further studies, Hispanic children have lower rates for 
food allergies than non-Hispanic white and black.31,38 There are socially constructed 
disparities that suggest difference in prevalence of food allergy by race and income.38 
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Modification of Ara h2 as a potential immunotherapy stimulant. Proteins of 
peanut allergens are generally stable under high pressures, varying temperatures and 
digestive conditions.20,39 One of the reasons for this is roasting the peanut which causes 
modification of lysine and possibly arginine residues by the Maillard reaction.40 The 
Maillard reaction is a nonenzymatic chemical modification between amino acids and 
reducing sugars when cooked at high temperature to form advanced glycation end-products 
(AGEs).41 Roasting induces protein structural changes that enhance allergenic properties 
of Ara h1 and Ara h2. The Maillard reaction explains stability of other food allergens as 
well in that it preserves protein structure and IgE-binding epitopes rendering them from 
digestion by specific peptides in the digestive tract.40,42 Thermal treatment also results in 
formation of variety of advanced glycation end products which increases the weight of the 
allergen. The increased weight of an allergen can potentially make the allergen more potent 
since the digestive enzymes are not able to access the cleavable sites.22,43  
It has been shown that boiling or frying of peanut matrix, as practiced in China, 
reduces the allergenicity of peanuts.44 This could explain why the prevalence of peanut 
allergy is increasing in the western world where roasting peanuts is more common 
compared to countries where peanuts are commonly prepared by boiling or frying such as 
China. Since most of the peanuts eaten in U.S. are in the form of roasted peanuts, it was 
important for us to use roasted peanuts in the development of an allergoid as potential 
therapeutic.  
There has been evidence of modification of IgE-binding epitope of peanut allergen 
to decrease serum IgE binding from peanut-hypersensitive patients and stimulate T-cell 
proliferation and activation.45-47 It has been studied that no specific epitopes were 
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associated with severe reactions to peanut and that clinical sensitivity is positively related 
to a more polyclonal IgE response.48 King et al.45 were able to engineer a mutant Ara h2 
that showed less binding to allergen-specific IgE which was able to interact with T-cells 
and release significantly lower amounts of mediators from passively sensitized mast cells 
thus lowering allergenicity. Another option to reduce allergen-specific IgE is to mask 
allergen epitopes by crosslinking protein via specific amino acid. Wu et al.47 were able to 
crosslink Ara h2 (either inter- or intramolecular) at tyrosine using polyphenol oxidase as 
catalyst. This allowed crosslinked Ara h2 to be more digestible by gastric fluid (however 
more difficult to digest by intestinal fluid) and a decrease in allergenicity was noted since 
three of the five tyrosine that were crosslinked were located in two of three main epitopes 
of Ara h2.47 Another study showed the combined effects of polyphenol oxidase and caffeic 
acid, a phenolic compound, leading to decreased IgE binding of Ara h1 and Ara h2 by 
cross-linking via tyrosine residues of protein 1 and protein 2.49-51 
There are various immunotherapies in the market for various pollen like ragweed 
or venom anaphylaxis such as wasp allergy but there is no FDA approved immunotherapy 
for food allergies.27 There has been a study done by Nelson et al.52 where they injected 
peanut extract into patients with peanut allergy using subcutaneous immunotherapy 
(SCIT). Their study concluded that due to over reaction in patients upon injection of peanut 
allergen that a modified peanut extract is needed instead of unmodified. This has opened 
doors to antigen-specific approaches to decreasing peanut allergenicity which include oral, 
sublingual, and epicutaneous immunotherapy.53 
 Oral immunotherapy (OIT) delivers antigens to the mucosal immune system via 
ingestion with absorption through the small intestine. OIT has been recently recognized 
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clinically to desensitize patients to peanut with suppression of mast cell and basophile 
activation along with increase in blocking peanut-specific IgG and IgG4 antibodies which 
compete with IgE for the binding of peanut proteins.54 These studies have been 
demonstrated in European countries as well such as Germany and England, however, OIT 
is still deemed as an experimental treatment and not ready for widespread 
implementation.27  
Sublingual immunotherapy (SLIT) delivers antigens to the oral mucosa by placing 
protein under the tongue. A recent study by Burks et al.55 was able to conclude that SLIT 
was able to desensitize peanut allergic patients with decreased immunologic activity over 
3 years along with excellent long-term safety profile. By the end of the study, 10.8% of 
patients were fully desensitized to 10 g of peanut powder, however, more than 50% 
discontinued therapy by the end of year 3.55  
 Another approach is epicutaneous immunotherapy (EPIT) which uses spray-dried 
allergens on a membrane applied to patient’s skin. The superiority of this therapy over OIT 
and SLIT is that the effect of peanut allergy is localized to the area of the patch and not 
systematic. A current treatment in clinical trials is Viaskin Peanut, which showed peanut 
EPIT administration was safe with reduced sensitivity to peanut and increased IgG4 levels 
and IgG4/IgE ratio along with reduced basophil activation and peanut-specific TH2 
cytokines. This study was after 52 weeks of treatment which showed higher success among 
younger children of age 4-11.56  
There are also non-antigen-specific approaches which involve administration other 
than the allergen to decrease allergenicity. There has been many anti-IgE therapy like 
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monoclonal antibody against human IgE, TNX-901 and antihuman IgE monoclonal Xolair 
(FDA approved but later discontinued) which have shown effectiveness by decreasing 
circulating IgE towards allergens and treating asthma, respectively. These anti-IgE 
therapies maybe impractical as they are expensive with lifelong injections to decrease 
continuous IgE proliferation in the body. There is an immunomodulatory phytochemicals 
category as well which are small molecules extracted from plants. This type of therapy has 
shown promise as a Chinese medicine called food allergy herbal formula-1 (FAHF-1), 
which contains 11 herbal extracts and FAHF-2 containing 9 herbal extracts in treatment of 
food allergy. FAHF-2 has been shown to decrease peanut, egg and fish allergy in murine 
study with no human trials. Recent study of FAHF-2 in human showed favorable in vitro 
immunomodulatory effects however with no improvement of tolerance to food allergens.57  
The future goal of this study in creating a modified Ara h2 protein is so that it can 
be utilized in OIT or for some patients allergic to peanut, SIT since it offers a long lasting 
clinical efficacy as well.58 The problem with using OIT or SIT to desensitize patient with 
peanut allergy is that the peanut proteins (especially Ara h2) are very potent leading to high 
risk of systemic adverse events such as anaphylaxis as show back in a study back in 1997.52 
Thus, if Ara h2 can be modified in a way to either mask or disrupt epitope binding amino 
acids, it can be used in a controlled dosage form to desensitize patient with peanut allergy, 




Purification of Ara h2 and Modification with Cross-linkers 
Introduction to Cross-linkers  
Cross-linkers are chemical reagents used to conjugate molecules together by the 
formation of covalent bond. Different cross-linkers have different functional groups that 
allow differential reactivity to specific target moiety. The cross-linkers used in this study 
were BS3 (bis(sulfosuccinimidyl) suberate, MW: 572.43, MF: C16H18N2Na2O14S2), DST 
(disuccinimidyl tartrate, MW: 344.24, MF: C10H12N2O10), Sulfo-EGS (ethylene 
glycolbis(sulfosuccinimidylsuccinate), MW: 660.45, MF: C18H18N2Na2O18S2), BM(PEG)3 
(1,11-bis(maleimido)triethylene glycol, MW: 352.34, MF: C16H20N2O7) and EDC (1-ethyl-












BS3, DST, and sulfo-EGS all contain N-hydroxysccinimide ester (NHS ester) that 
react with nucleophiles to release the NHS or sulfo-NHS leaving group and form an 
acylated product with varying spacer arm length (reaction schematic described below).59 
NHS ester can react with sulfhydryl or hydroxyl group but the conjugation is not stable and 
it can be hydrolyzed in aqueous solutions. Reaction with primary and secondary amines is 












































































contain primary amines for reaction can be seen in Figure 3 which was created using VMD 
software.26 BM(PEG)3 cross-linker has maleimide group on each side which helps 
conjugate between sulfhydryl groups. BM(PEG)3 contains a poly(ethylene glycol) (PEG) 
as spacer arms which helps make PEG cross-linker hydrophilic compared to hydrocarbon 
spacers. EDC is a carboxyl and amine-reactive zero-length cross-linker that forms amide 
bonds. It is named zero-length cross-linker since the bond formed between the conjugates 










BS3 is a homobifunctional NHS ester crosslinking reagent that adds an eight-atom 
bridge (11.4 Å) between conjugated molecules.61 This reagent is forming irreversible bond 
with the protein since the hydrocarbon chain is non-cleavable. The sulfonate groups give a 
negative charge to the molecule making it water soluble. NHS esters are reactive towards 
primary amino groups (-NH2) in pH 7 to 9 buffers to form stable amide bonds. The 
recommended buffers to use are amine free such as Tris, glycine, or imidazole buffers so 
that the amines from the buffer do not cross-react with the NHS ester. The NHS ester forms 
amide linkages with α-amines and ε-amines of proteins like primary amines on the side 
chain of lysine residues and on the N-terminus of each polypeptide making them a good 





Figure 4. Reaction schematic of cross-linker BS3. An amide bond is formed leading to 





DST is a homobifunctional NHS ester crosslinking reagent that contains a central 
diol that is cleavable by sodium periodate thus making the conjugation reversible.62 The 
reagent adds 6.4 Å of space between conjugated molecules. DST is not so soluble in 
aqueous buffers thus it needs to be pre-dissolved in organic solvents such as THF, DMF, 
or DMSO prior to addition with molecules that need to be conjugated. The recommended 
buffer to use are amine free such as Tris, glycine, or imidazole buffers with optimal pH of 
7 to 9. As mentioned before, conjugation with this cross-linker can be cleaved using 0.015 








Figure 5. Reaction schematic of cross-linker Sulfo-EGS. An amide bond is formed leading 





Sulfo-EGS is a homobifunctional crosslinking agent that contains NHS ester groups 
on the ends as well. Middle of the reagent is constructed from an ethylene glycol group 
esterified on either side with succinic acid. Sulfo-EGS is water soluble due to the negatively 
charged sulfonate groups on its NHS rings. This reagent adds a space of 16.1 Å between 
the conjugated molecules.59 The NHS esters are reactive towards amines thus an amine 
































































central bridge of EGS provides two cleavable ester sites at pH 8.5 by incubation with 1-M 
hydroxylamine for 3 to 6 hours at 37° C.60,63 A reaction schematic can be seen in Figure 6 





Figure 6. Reaction schematic of cross-linker DST. An amide bond is formed leading to 





















































BM(PEG)3 contains bifunctional thiol reactive maleimides on each end that 
produces stable thioether linkages with sulfhydryls.64 The cross-linker is hydrophilic with 
spacer arm of 17.8 Å. BM(PEG)3 is recommended in pH range of 6.5 to 7.5 for reaction 
towards sulfhydryl groups and pH of >8 for primary amines, however, reaction rate is 1000 
times slower with amines. Sodium phosphate (0.01-0.1 M) buffer works well for this 
reaction making sure to avoid amine-containing buffers along with sulfhydryl-containing 
disulfide reductants such as DTT or 2-mercaptoeathanol. A 3D molecular modeling of Ara 
h2 showing disulfide bonds can be seen in Figure 7 that was created using VMD software.26 
Maleimide moiety can hydrolysis resulting in opening of the maleimide ring rendering it 















Figure 8. Reaction schematic of cross-linker BM(PEG)3. Formation of thioether linkages 




EDC is a carbodiimide with a zero-length crosslinking arm that forms an amide or 
phosphoramidate linkage between a carboxylate group and an amine or a phosphate and an 
amine, respectively. A 3D molecular modeling of Ara h2 showing Asp and Glu residues 
can be seen in Figure 9 that was created using VMD software.26 EDC reacts with carboxylic 
acid to form an amine-reactive O-acylisourea intermediate that will react with a 
nucleophile such as a primary amine to form an amide bond and release an isourea by-
product as seen in Figure 10. Consideration should be given to the intermediate since it is 
unstable in aqueous solutions. Oxygen atoms can also act as a nucleophile as in water 
molecules thus resulting in activation of EDC and hydrolysis of the activated ester 
intermediate, regenerating the carboxylate group and release of an N-substituted urea.65 
Buffers such as MES [2-(N-morpholino)ehane sulfonic acid] at 0.1-M works well at acid 
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any buffer that does not contain amines or carboxylic groups or other components that may 













Figure 10. Reaction schematic of cross-linker EDC. Amide bond formation using EDC 




The carboxylate activation is most efficient at pH 3.5 to 4.5, while amide bond 
formation occurs with highest yield at pH 4 to 6 thus a two-step coupling can be used 
(Figure 11). Since there are many by-products that can be formed, sulfo-NHS can be used 
to increase the solubility and stability of the active intermediate.66 The active ester, O-
acylisourea, is slow to react with amines and can hydrolyze in aqueous solution so 
introduction of sulfo-NHS to the active intermediate allows sulfo-NHS ester to form. This 
sulfo-NHS ester intermediate is more effective at reacting with amine and thus a higher 







Figure 11. Two-step coupling reaction schematic of EDC and sulfo-NHS. Efficiency of 
reaction with EDC can be increased by introduction of sulfo-NHS and forming a sulfo-




Research Design and Methods  
Protein purification method 1. Ara h2 protein was purified according to Sen et 
al.20 with few personal modifications. Roasted, unsalted peanut seeds (Arachis hypogaea, 
hypogaea hypogaea) were obtained from Good Earth Peanut Co., Skippers, VA, USA. 
Peanut seeds were crushed after freezing them with liquid nitrogen using a mortar and 
pestle. Crushed peanuts were placed in a cellulose extraction thimble which was placed in 
a soxhlet extraction for defatting with three changes of diethyl ether. Defatted peanut seeds 
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were dried by spreading them out on a paper towel over night under the hood. The dried 
defatted peanut seeds were crushed into a fine powder using mortar and pestle.  
Peanut flour was dissolved in TBS buffer (65 mM Tris-HCl, 1 mM EDTA, 1 mM 
PMSF, pH 8.3) with 200 mM NaCl at a ratio of 1 gram to 50 mL buffer. The mixture was 
sonicated using Sonics Vibra-Cell at 39% power for 10 mins over ice followed by 1 hour 
of stirring at room temperature. The dissolved peanut suspension was then followed by 
vacuum filtration thru six layers of cheesecloth. The filtered solution was centrifuged 
(Sorvall RC 5B PLUS, SS-34 rotor) at 30,000 X g for 30 mins at 4° C. The supernatant 
was fractionated using ammonium sulfate precipitate (NH4)2SO4 (MW 132.14) going from 
0 to 40% carrying the supernatant and then carrying the pellet in 40% to 70% precipitate. 
The ammonium sulfate was added slowly over 30 min period and stirred for total of 1 hour 
over ice followed by centrifugation at 30,000 X g for 30 mins (SS-34 rotor). 
The pellet was dissolved in 10 mL of TBS buffer without NaCl followed by 
sonication for 1 min at 39% power (over ice) and centrifugation (3,000 X g for 15 min) to 
remove undissolved particles. The supernatant was dialyzed (SnakeSkin Dialysis Tubing, 
7K MWCO) overnight against TBS buffer to remove salts from the mixture. The 
supernatant was loaded onto a flex-column 1.5 x 30 cm (Kimble Chase) filled with 
approximately 50 mL of Q Sepharose Fast Flow (GE Healthcare) that had been equilibrated 
with TBS buffer. After loading the supernatant, 90 mL of TBS buffer with 40 mM NaCl 
was used to elute proteins of noninterest. Then a linear gradient of 400 mL using 200 mL 
TBS buffer with 40 mM NaCl to 200 mL TBS buffer with 500 mM NaCl was used to elute 
protein of interest at a flow rate of 2 mL/min. Fractions were collected for 1 min 15 secs 
per tube to give approximately 2.5 mL per tube. 
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The fractions were analyzed using coomassie G-250 dye bonding assay for protein 
in a clear 96-well plate. Ratio of 50 µL protein sample to 150 µL coomassie dye was used 
followed by reading of the plate at 595 nm (Thermo Scientific Multiskan Spectrum). 
Positive fractions were analyzed using SDS-PAGE (see below “SDS-PAGE protocol”) for 
Ara h2 followed by dialyses (7K MWCO) overnight at 4° C against 25 mM Tris-HCl (pH 
7.4) and 3 M NaCl. The dialyzed sample was loaded onto a flex-column 1.5 x 30 cm 
(Kimble Chase) filled with approximately 50 mL of Phenyl Sepharose 6 Fast Flow (high 
sub) (GE Healthcare) that had been equilibrated with 25 mM Tris-HCl (pH 7.4) with 3 M 
NaCl. After loading, a linear gradient of 200 mL using 100 mL of 25 mM Tris-HCl buffer 
with 3 M NaCl to 100 mL of 25 mM Tris-HCl buffer with 0 M NaCl was ran at 1.5 mL/min. 
Fractions were collected for 1 min 20 secs per tube to give approximately 2.0 mL per tube.  
Fractions were analyzed again for Ara h2 using coomassie G-250 dye bonding assay and 
SDS-PAGE. Ara h2 containing fractions were pooled and dialyzed (7K MWCO) overnight 
at room temperature against 15 mM ammonium bicarbonate (pH 7.0). The dialyzed sample 
was lyophilized (FreeZone 2.5 L Benchtop Freezer Dry System, Labconco) and stored at -
20° C. 
Protein purification method 2. A second, novel method for purifying Ara h2 was 
developed to increase yield and efficiency of the purification process. This method of 
purification was inspired by Jumnongpon et al.69 as they purified cocoa protein from cocoa 
beans. Cocoa beans consist of 52% albumin and 43% globulins and peanut protein Ara h2 
is from the albumin family thus it warranted us to utilize this purification method.  
Peanuts were defatted and crushed into fine powder as described above in method 
1. The peanut proteins were, however extracted using 0.5% SDS-0.05 M phosphate buffer, 
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pH 6.9 instead of TBS buffer. Peanut powder (0.1 g) was weighed into 1.5 mL Eppendorf 
tubes and combined with 1 mL of extraction buffer (multiple batches done at once). The 
Eppendorf tubes were placed in a water sonication bath (Model 50T, VWR) for 1 hour 
changing the water to keep the water temperature constant at room temperature. After 1 
hour, the samples were centrifuged (Allegra 21 Centrifuge, Beckman) at 3,000 X g for 10 
mins taking the supernatant out. The precipitates were further extracted by adding 1 mL of 
extraction reagent buffer to the Eppendorf tubes followed by 1 hour water sonication bath 
and centrifugation at 3,000 X g for 10 mins. The supernatant was combined and pellets 
discarded.   
 The supernatant was filtered using a Whatman syringe filter 1.0 µm GF/B w/GMF 
and placed in dialysis tubing (7K MWCO) to be dialyzed against 15 mM ammonium 
bicarbonate (5 L bucket) with minimum of 6 changes at 4° C. The extract was then 
lyophilized and protein powder (0.050 g) dissolved in 10 mL of TBS buffer (65 mM Tris-
HCl, 1 mM EDTA, 1 mM PMSF, pH 8.3). The solution was then loaded (10 mL) onto a Q 
Sepharose Fast Flow (GE Healthcare) column that was packed with approximately 100 mL 
of resin in Flex-Column 2.5 x 30 cm (Kimble Chase). The column was washed with 100 
mL TBS buffer containing 40 mM NaCl at flow rate of 2 mL/min to elute proteins of 
noninterest. Then a linear gradient of 400 mL using 200 mL TBS buffer with 40 mM NaCl 
to 200 mL TBS buffer with 500 mM NaCl was used to elute protein of interest at a flow 
rate of 2 mL/min. Fractions were collected for 1 min 15 secs per tube to give approximately 
2.5 mL per tube. 
The fractions were analyzed for protein as described above in Method 1 using 
coomassie G-250 dye bonding assay followed by SDS-PAGE gel to identify fractions 
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containing Ara h2. Fractions of interest were collected and dialyzed (7K MWCO) 
overnight at room temperature against 15 mM ammonium bicarbonate (pH 7.0) followed 
by lyophilization. The sample was resuspended in dH2O (Milli-Q ultrapure) and subjected 
to centrifugal filters of 30K MWCO to remove proteins greater than or equal to 30 kDa 
(Amico Ultra-15, Ultracel-30K, Merck Millipore). The centrifuged protein was verified for 
purity by SDS-PAGE, lyophilized and stored at -20° C.  
  BS3 reaction. Protein powder that had been lyophilized was dissolved in 20 mM 
HEPES, pH 8 buffer to give a concentration of 12 mg/mL as confirmed by BSA standard 
curve. This dissolved protein was used as a stock to separated and diluted by two-fold to 
give two different concentrations, 6 mg/mL and 12 mg/mL. BS3 (Lot #PD198244, prod. # 
21580, Thermo Scientific) was dissolved in 20 mM HEPES, pH 8 buffer to obtain 
concentrations of 100, 50, 25, and 12.5 mM. These concentrations were created in 
duplicates to accompany the two separate protein concentrations. The cross-linker was 
prepared immediately before adding to the protein to prevent from hydrolysis of NHS ester.  
The dissolved protein and BS3 solution was added at a 1:1 volume ratio (35 µL:35 
µL) followed by incubation for 30 mins at room temperature followed by SDS-PAGE 
analysis (Figure 12a). After 30 mins of incubation at room temperature, samples were 
placed at 37° C for continued reaction with cross-linker followed by SDS-PAGE analysis 
after 2 days (Figure 12b) and 6 days (Figure 12c) (Gel from Thermo Scientific, 2x sample 
buffer & marker from Novagen). Due to 1:1 ratio, the final protein concentration and BS3 
cross-linker concentration was cut in half. This gave final protein concentration of 6 
mg/mL from 12 mg/mL and 3 mg/mL from 6 mg/mL. The final concentration of cross-
linker was 50, 25, 12.5, and 6.25 mM from initial 100, 50, 25, and 12.5 mM, respectively.  
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Another condition of increasing the pH from 8 to 10.7 was tested to see if cross-
linking can be enhanced with BS3. Same conditions as above were used, however, only one 
protein concentration of 6 mg/mL was tested instead of both. Again, fresh batch of BS3 
was prepared at concentrations of 100 mM to 12.5 mM as above. The reaction was 
completed in duplicate so that one set can be placed at room temperature and the other in 
the incubation at 37° C. The reaction mixture was allowed to incubate followed by SDS-
PAGE analysis after 1 day (Figure 13a) and 4 days (Figure 13b) (Gel from Thermo 
Scientific, 2x sample buffer & marker from Novagen). Same ratio of protein to cross-linker 
was used as above at 1:1 volume ratio (35 µL: 35 µL) diluting the protein and cross-linker 
concentration by half. This gave final protein concentration of 3 mg/mL from 6 mg/mL 
and final concentration of cross-linker of 50, 25, 12.5, and 6.25 mM from initial 100, 50, 
25, and 12.5 mM, respectively. 
Since the NHS ester is reactive towards sulfhydryl and primary amine groups, a 
reducing agent 2-mercapaptoethanol was added to reduce disulfide bonds and open the 
structure so that more possible reactive sites can be accessed by BS3. Lyophilized protein 
powder was dissolved in 20 mM HEPES, pH 8.0 buffer and separated in duplicates. To 
one protein solution, 1.4 µL of 2-mercaptoethanol was added after 15 mins of incubating 
the protein at 37° C. Fresh BS3 was prepared immediately before adding to the protein at 
concentrations from 35 mM to 65 mM in 5 increments. Protein and cross-linker were added 
at 1:1 volume ratio (50 µL:50 µL) followed by incubation at 37° C.  
Due to 1:1 ratio, the final protein concentration and BS3 cross-linker concentration 
was cut in half. This gave final protein concentration of 2 mg/mL from 4 mg/mL of protein. 
The final concentration of cross-linker was 32.5, 30.0, 27.5, 25.0, 22.5, 20.0, and 17.5 mM 
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from initial 65, 60, 55, 50, 45, 40, and 35 mM, respectively. Since no reaction was observed 
within 30 mins or 2 days of incubation, an SDS-PAGE analysis was performed after 5 days 
of incubation (Figure 14) (Gel from Thermo Scientific, 2x sample buffer & marker from 
Novagen). Before loading the protein onto the gel, 0.5 µL of 1 M glycine was added to 10 
µL of protein and cross-linker solution to quench any unreacted cross-linkers in the 
solution. Then 10 µL of 2x Laemmli sample buffer was added to the quenched solution 
which turned green/yellow due to pH change. Thus, to bring the solution back to blue, 1 
µL of 1 M NaOH was added to the solution. 
Sulfo-EGS reaction. Protein powder that had been lyophilized was dissolved in 20 
mM HEPES, pH 8 buffer and 20 mM HEPES, pH 10.7 buffer to give concentrations of 8.6 
mg/mL and 11.6 mg/mL, respectively, as confirmed by BSA standard curve. Sulfo-EGS 
(Lot #CK2606, prod. #C1129, ProteoChem) was dissolved in 20 mM HEPES, pH 8 buffer 
and 20 mM HEPES, pH 10.7 buffer to obtain concentrations of 10, 5, 2.5, and 1.25 mM. 
These concentrations were created in four sets to accompany the two-different pH and two 
different temperature conditions. The cross-linker was prepared immediately before adding 
to the protein to prevent hydrolyzes of NHS ester. 
The dissolved protein and Sulfo-EGS solution was added at a 1:1 volume ratio (37.5 
µL:37.5 µL). Due to 1:1 ratio, the final protein concentration and Sulfo-EGS cross-linker 
concentration was cut in half. This gave final protein concentration of 4.3 mg/mL from 8.6 
mg/mL and 5.8 mg/mL from 11.6 mg/mL. The final concentration of cross-linker was 5, 
2.5, 1.25, and 0.625 mM from initial 10, 5, 2.5 and 1.25 mM, respectively. One sample 
with buffer at pH 8 was incubated at room temperature (Figure 15a) and another at 37° C 
(Figure 15b). Same was done for reaction mixture with buffer at pH 10.7, one at room 
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temperature (Figure 15c) and another at 36° C (Figure 15d). An SDS-PAGE analysis was 
done 54 days after due to insufficiency of SDS-PAGE gels at the time (Gel from Thermo 
Scientific, 2x sample buffer & marker from Novagen). 
DST reaction. Protein powder that had been lyophilized was dissolved in 20 mM 
HEPES, pH 10.7 buffer to give concentration of 4 mg/mL, as confirmed by BSA standard 
curve. Since the NHS ester is reactive towards sulfhydryl and primary amine groups, a 
reducing agent 2-mercapaptoethanol was added. The protein was split with one having 2-
mercaptoethanol (added after incubating protein at 37° C for 15 mins) and one without. 
DST (Lot #DD2687, prod. #C1133, ProteoChem) was dissolved in 20 mM HEPES, pH 
10.7 buffer. DST is not soluble in HEPES buffer so DMSO (7% final concentration) was 
used to dissolve the cross-linker. The same amount of DMSO was also added to the control 
protein.  
A serial dilution was carried out from 25 mM to 3.125 mM with 4 total 
concentrations. The dissolved protein and DST solution was added at a 1:1 volume ratio 
(50 µL:50 µL). Due to 1:1 ratio, the final protein concentration and Sulfo-EGS cross-linker 
concentration was cut in half. This gave final protein concentration of 2 mg/mL from 4 
mg/mL. The final concentration of cross-linker was 12.5, 6.5, 3.1, and 1.6 mM from 25, 
12.5, 6.3, and 3.1 mM, respectively. Protein was incubated at 37° C followed by SDS-
PAGE analysis 2 days later (Figure 16) (Gel from Thermo Scientific, 2x sample buffer & 
marker from Novagen). Before running the gel, 0.5 µL of 1 M glycine was added to quench 
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any unreacted cross-linkers in the solution followed by 2x Laemmli sample buffer and 1 
µL of 1 M NaOH to turn the solution back to blue from the pH change. 
BM(PEG)3 reaction. Protein powder was dissolved in 20 mM HEPES, pH 8 to 
give a concentration of 4 mg/mL as confirmed by BSA standard curve. Since BM(PEG)3 
is a cross-linker that conjugates between sulfhydryl groups, the protein had to be reduced 
and this was carried out by using immobilized TCEP disulfide reducing gel (Thermo 
Scientific). To test the reducing activity of TCEP, Ellman’s reagent was used which did 
confirm the gel was active after color change to yellow. The dissolved protein was added 
to TCEP resin that was equilibrated with 20 mM HEPES, 20 mM EDTA, pH 8 by vortexing 
for 1 min followed by centrifuge at 1,000 X g and removing supernatant. The protein (250 
µL) and resin (500 µL) mixture was mixed in an Eppendorf tube and stirred for 2 hours at 
room temperature followed by centrifuge at 1,000 X g for 1 min, carrying the supernatant. 
Another 100 µL of buffer was added to the Eppendorf tube to extract any remaining protein 
from the resin mixture.  
BM(PEG)3 (Lot # RA230660, Prod # 22337, Thermo Scientific) was dissolved in 
DMSO (13.3%) followed by serial dilution to obtain following concentrations: 153.26, 
76.63, 38.32, 19.16, 9.58, 4.79, 2.39, 1.20, 0.60, and 0.30 mM.  Cross-linker was prepared 
and covered in foil to protect from light immediately before adding to already reduced 
protein. Added 130 µL of reduced protein and 20 µL of cross-linker at varying 
concentrations. Samples were incubated at room temperature followed with SDS-PAGE 
analysis after day 1 (Figure 17a) and day 7 (Figure 17b). (Gel from Bio-Rad, 5x sample 
buffer & marker from Bio-Rad). Final protein concentration was 3.5 mg/mL and final 
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cross-linker concentrations were: 20.43, 10.22, 5.11, 2.55, 1.28, 0.639, 0.319, 0.160, 
0.0798 and 0.0399 mM. 
EDC reaction. In order to modify/mask IgE binding epitopes of Ara h2, a peptide 
called TV1 (sequence: MDAEFRHDS-NH2, MW: 1107.2) was reacted in the presence of 
EDC. This was carried out in order to crosslink with one of the amino acids on the epitopes 
or at least mask the epitope sites with the peptide. Protein was reacted with cross-linker 
EDC and sulfo-NHS via 2-step reaction since it is more efficient as described above. Since 
Ara h2 has high percentage of glutamic acid and aspartic residues, it was used in the 
activation reaction with EDC. The activation buffer is recommended to have pH between 
4.5-7.2 (without amines or carboxylate in the buffer) so 4-Morpholineethanesulfonic acid 
(MES) was used.  Activation buffer consisted of 0.1 M MES, 0.5 M NaCl, pH 5.0 that was 
used to dissolve the protein for a protein concentration of 8.0 mg/mL as confirmed by a 
BSA standard curve.  
Since coupling buffer is recommended to be at pH 7-8, a phosphate-buffered saline 
(PBS) was used (100 mM sodium phosphate, 150 mM NaCl, pH 7.2). The TV1 peptide 
was dissolved in PBS buffer to give a concentration of 1.5 mM. EDC was equilibrated to 
room temperature before opening. To the activated protein in MES buffer, 2 mM of EDC 
and 5 mM of sulfo-NHS was added and allowed to react for 15 mins at room temperature. 
The reaction was quenched of unused EDC by adding 2-mercaptoethanol at a final 
concentration of 20 mM. Peptide containing solution was added to the quenched activated 
protein solution and allowed to react for 2 hours at room temperature. Final concentration 
of protein was 4 mg/mL since 1:1 volume ratio of Protein and TV1 peptide was used. The 
whole reaction was quenched by adding hydroxylamine at final concentration of 10 mM 
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which hydrolyzes nonreacted NHS present on the protein and results in hydroxamate. An 
SDS-PAGE analysis (Figure 18) was done after quenching the reaction using gel from 
Thermo Scientific, 2x sample buffer & marker from Novagen.  
SDS-PAGE protocol. Two different brands of sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gels were used, however, both contained 
the same polyacrylamide gradient of 4% to 20%. A 4-20% Mini-PROTEAN TGX (Tris-
Glycine eXtended) Precast Protein Gels, 12-well, 20 µL from Bio-Rad and another a 4-
20% Precise Tris-Glycine Precast Gels, 12-well, 20 µL from Thermo Scientific. A 2x 
Laemmli sample buffer or 5x Laemmli sample buffer was used that was made according 
to Cold Spring Harbor Protocols (120 mM Tris-Cl, 4% SDS, 20% v/v glycerol, 0.2 M DTT, 
0.02% w/v bromophenol blue, pH 6.8). Two different protein markers were used for 
reference on the SDS-PAGE gels. Commercially available Protein Marker, (Novagen) with 
molecular weights of 15, 25, 35, 50, 75, 100 and 150 kDa was used when gel from Thermo 
Scientific was run or Precision Plus Protein Standards Dual Color (Bio-Rad) with 
molecular weights of 10, 15, 20, 25, 37, 50, 75, 100, 150 and 250 kDa was used when gel 
from Bio-Rad was used. Gel was running at 110 V until the dye front reached the bottom 
of the gel. Gel was stained with staining solution created with Coomassie brilliant blue R-
250 followed by de-staining until bands were visible. Gel was imaged using Azure 
Biosystems c300. 
Results and Discussion 
NHS ester reactions. BS3 reaction without any addition of 2-mercaptoethanol was 
tested to see if protein can be modified without reduction. The protein used for this batch 
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was not pure with just Ara h2 as it has other proteins as seen in Figure 12(a, b, c), lanes 2 
& 8 (control lanes) for concentrations of 12 mg/mL and 6 mg/L, respectively. The purpose 
of this reaction was a prove of concept to see if any cross-linked dimer or oligomers are 
observed with BS3 cross-linker. As seen by the SDS-PAGE gel in Figure 12(a, b, c) that 
there was disappearance of Ara h1 as the concentration of cross-linker was increased from 
left to right. This is possibly proving that Ara h1 was cross-linked and due to high MW, it 
could have precipitated out of solution without being loaded onto the gel.  
Protein Ara h2 after 30 mins of incubation at room temperature Figure 12(a) with 
BS3 appears to have little effect as noted by the same density of the protein bands as 
concentration of cross-linker is increased from left to right on the SDS-PAGE. There is 
slight decrease in intensity of Isoform Ara h2.02 in Figure 12(a), lane 12 which could 
possibly have cross-linked and precipitated out of solution. However, after placing this 
same protein/cross-linker mixture at 37° C followed by SDS-PAGE analysis 2 days (Figure 
12(b)) and 6 days (Figure 12(c)) after showed Ara h2.01 and Ara h2.02 band intensity 
decrease, almost nothing to very faint. This was only observed at the highest cross-linker 
concentration of 50 mM BS3 (Figure 12(b, c) lanes 6 & 12). There are two possible reasons 
that Ara h2 band intensity decreases with no possible dimerization or multimerization. One 
reason is that the protein could have cross-linked with decreased solubility causing the 
protein to precipitate out of the solution. The other reason is that the high concentration of 
BS3 could have some effect on the SDS-PAGE gel. 
BS3 was tested with different pH as well to see if that would promote cross-linking 
among peanut proteins thus pH was changed from 8 to 10.7. Protein and cross-linker were 
incubated for 1 day (Figure 13(a)) and 4 days (Figure 13(b)) followed by SDS-PAGE 
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analysis. Batch was split in half with one at room temperature and other at 37° C. It can be 
seen that as concentration of BS3 is increased from left to right, there is a decrease in protein 
band intensity of Ara h2, Ara h1 and Ara h3. As for the highest concentration of BS3 there 
is a disappearance of all the proteins from that lane as compared to the control lane. This 
could be due to the protein being cross-linked and precipitating out of the solution or it 
could be that particular concentration of BS3 could be have a reaction with the SDS-PAGE 
gel, however, this is undetermined and an area for future investigation. 
Since BS3 reaction without 2-mercaptoethanol showed little evidence of 
dimerization or oligomerization, another set of reactions were set up that included the 
reducing agent 2-mercaptoethanol. Since this batch of protein was different, both non-
reducing and reducing conditions were used. It can be seen from Figure 14(a) and 14(b) 
that there is no dimer or oligomers observed on the SDS-PAGE gel. What can be noticed 
is that the decrease in intensity of protein is observed compared to the control. This is 
observed in both the reducing and non-reducing conditions of the protein. This means that 
it must be BS3 interfering with the SDS-PAGE gel and causing the band intensity to 
decrease and not the reducing agent.  There is a decrease in Ara h1 as noticed with protein 
band disappearance. Thus, it is highly likely that BS3 has reactivity towards Ara h1 and 
possibly some reactivity towards Ara h2 at 50 mM BS3 concentration. Since Ara h1 is also 
a major peanut allergen, this can be of a further study by isolating and reacting Ara h1 with 
cross-linker. Further testing is required to confirm if Ara h2 concentration has decreased 
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due to modification or cross-linker by testing patient’s IgE reactivity to the modified 
protein in an ELISA or Western Blot assay. 
Protein reaction with Sulfo-EGS cross-linker showed no new formation of dimer 
or oligomer (Figure 15). The SDS-PAGE gels from Figure 15(a, b, & c) show no reactivity 
as the band intensity of Ara h2 protein (or any other protein on the gel) have not decreased 
along with no new bands as compared to the control. Even trying two different pH (8 & 
10.7) and two different temperature (room temperature & 37° `C) showed no sign of cross-
linking. Gel from Figure 15(d) (lane 6) shows possible crosslinking with new bands 
appearing between 60-70 kDa as compared to the control. Lane 7 which is the next higher 
concentration of cross-linker shows decrease in Ara h2.02 band however no new band 
formation to indicate cross-linking. Upon repeating the SDS-PAGE (data not shown) with 
same condition, there was no evidence of those bands, which indicate that those bands 
between 60-70 kDa were from some other impurities. It could be possible that upon 
repeating the SDS-PAGE gel, the cross-linked protein might have precipitated out and was 
not being loaded into the well. 
DST cross-linker was applied which was dissolved in 7% DMSO. This same 
percentage of DMSO was also added to the control Ara h2 protein as well. DST was reacted 
with Ara h2 for 2 days (Figure 16) followed by SDS-PAGE gel to observe for cross-linking 
between protein. Protein was split into duplicate with one set having 2-mercaptoeathanol 
and the other without it. As seen on the gel, there is no new formation of dimer or oligomer. 
What can be seen is in lanes 5 & 10 a decrease in band intensity of Ara h2 which is at the 
highest concentration of DST used (12.5 mM). This can be due to two reasons; if Ara h2 
did cross-link, it could have precipitated out or DST itself at that concentration could be 
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interacting with the SDS-PAGE gel. Again, this has to be further tested by using IgE from 










Figure 12. SDS-PAGE of BS3 cross-linker in pH 8. SDS-PAGE after 30 mins (a) of 
reaction with BS3 in 20 mM HEPES, pH 8 at room temp. SDS-PAGE after 2 days (b) of 
reaction with BS3 in 20 mM HEPES, pH 8 at 37°C. SDS-PAGE after 6 days (c) of reaction 
with BS3 in 20 mM HEPES, pH 8 at 37°C. Lanes: (1 & 7) molecular marker (2 & 8) control 
(3 to 6 & 9 to 12) 6.25 mM to 50 mM of BS3 left to right. Concentration of protein in lanes 





Figure 13. SDS-PAGE of BS3 cross-linker in pH 10.7. SDS-PAGE after 1 day (a) and 4 
days (b) of reaction with BS3 in 20 mM HEPES, pH 10.7 at room temp and 37°C. Lanes: 
(1 & 7) molecular marker (2 & 8) control (3 to 6 & 9 to 12) 6.25 mM to 50 mM of BS3 left 
to right. Lanes (2 to 6) are samples incubated at 37°C and (8 to 12) are samples incubated 






Figure 14. SDS-PAGE of BS3 cross-linker in pH 8 with and without 2-mercaptoethanol. 
SDS-PAGE after 5 days of reaction with BS3 in 20 mM HEPES, pH 8 at 37°C. (a) Protein 
plus BS3 without 2-mercaptopethanol (b) Protein plus BS3 plus 2-mercaptoethanol. Lanes: 
(a)(1) molecular marker (2) control without 2-mercaptoethanol and (3 to 9) 17.5 mM to 
32.5 mM in 5 increments. (b)(1) molecular marker (2) control without 2-mercaptoethanol 
(3) control with 2-mercaptoethanol (4 to 10) 17.5 mM to 32.5 mM left to right. Final 





(c)   (d) 
Figure 15. SDS-PAGE of Sulfo-EGS cross-linker. SDS-PAGE after 54 days of reaction 
with Sulfo-EGS in 20 mM HEPES, pH 8 and pH 10.7 at room temp and 37°C. (a) pH 8 
at room temp. (b) pH 8 at 37°C (c) pH 10.7 at room temp. (d) pH 10.7 at 37°C. Lanes: 
(1a,b,c,d) molecular marker (2a,b,c,d) control (3 to 7) 0.625 mM to 5 mM of Sulfo-EGS 




Figure 16. SDS-PAGE of DST cross-linker. SDS-PAGE after 2 days of reaction with DST 
in 20 mM HEPES, pH 10.7 at 37°C. Lanes: (1) control with 2-mercaptoethanol (6) control 
without 2-mercaptopethanol (11) molecular marker ((2 to 5) with 2-mercaptoethanol & (7 
to 10) without 2-mercaptoethanol) 1.6 mM to 12.5 mM of DST left to right. Final 




Sulfhydryl reaction using maleimide. BM(PEG)3 was reacted with Ara h2 protein 
for 1 day (Figure 17(a)) and 7 days (Figure 17(b) followed by SDS-PAGE analysis. As 
seen by the SDS-PAGE gel after 1 day and 7 days of incubation, there is no formation of 
dimer or oligomer. As a reminder, no reducing agent was added to this batch since TCEP 
resin was used to reduce protein before addition of cross-linker. There is a possibility that 
the cross-linker might have attached to one or more sulfhydryl groups of cysteine residues 
but not cross-linked with another protein which could be due to steric hindrance. The cross-
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linker could have been inserted between the sulfhydryl groups but since the cross-linkers 






Figure 17. SDS-PAGE of BM(PEG)3 cross-linker. SDS-PAGE after 1 day (a) and 7 days 
(b) of reaction with BM(PEG)3 in 20 mM HEPES, pH 8 at room temp. Lanes: (1) 
molecular marker (2) control (3 to 12) 0.0399 mM to 20.43 mM of BM(PEG)3 from left to 
right. Final concentration of protein at 3.5 mg/mL. 
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Amide bond formation between carboxylic acid and primary amine. EDC was 
used to try and conjugate Ara h2 with TV1 peptide using 2 step conjugation reaction with 
sulfo-NHS. As seen by SDS-PAGE in Figure 18 that there is no dimer or oligomerization 
observed. There are multiple possibilities why this is observed. Since the peptide is small 
with low molecular weight, it possibly could have attached itself to the protein but just not 





Figure 18. SDS-PAGE of EDC cross-linker. SDS-PAGE of reaction of Ara h2 with TV1 
peptide using cross-linker EDC with sulfo-NHS in a 2-step reaction. Lanes: (1) control 




One test that can be employed on all the cross-linker is to do mass spectroscopy to 
see if the weight of the protein changed before and after addition of cross-linker. Another 
test can be tried to validate for the secondary structure of protein by using Circular 
Dichroism spectroscopy. Again, all these cross-linker could have attached to the protein 
and disrupted molecular binding between the proteins without actually conjugating with 
another protein but due to low molecular weight of cross-linker, they are not detectable by 
SDS-PAGE analysis. Thus, to really confirm a change in protein structure or addition of 
one or two cross-linkers without conjugation to another protein, an ELISA or Western Blot 
analysis can be carried out with IgE from patient serum that are allergic to peanut allergy.  
Method 1 vs method 2. Most important part of cross-linking Ara h2 was to purify 
Ara h2 from peanuts at a continuous and efficient way so other parts of the research are not 
hindered. Basically, purification of protein from peanut seeds was the rate determining step 
in this study. The procedure that was used to in the beginning of this study was method 1. 
This procedure involved 2 different chromatography columns with multiple steps utilizing 
many resources and time. Thus, method 2 was derived which involved only one 
chromatography column with fewer steps involving fewer resources and saving time. 
Both method 1 and method 2 begins by defatting crushed peanut seeds using 
Soxhlet extraction in ether solvent. The next step was dissolving this defatted peanut 
powder in buffer and this is where the two methods make their first split. Method 1 used 
TBS buffer and Method 2 used phosphate buffer with 0.5% SDS. Method 2 originally used 
two different buffers to extract proteins: 0.5% SDS + 0.02 M phosphate buffer, pH 6.9 
(“0.5% SDS” buffer hereafter) and 8 M Urea + 1% 2-mercaptoethanol (“8 M Urea” 
hereafter). Both buffers showed different proteins that were extracted as seen by SDS-
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PAGE (Figure 19). Lane 2 & 3 contain protein that had been extracted, dialyzed (overnight 
against dH2O), and lyophilized using 8 M Urea and 0.5% SDS, respectively. Protein 
powder extracted using 8 M Urea (0.0038 g) and 0.5% SDS (0.0037 g) was dissolved in 1 
mL of 20 mM HEPES, pH 8. Lanes 4 & 5, 8 M Urea and 0.5% SDS, respectively, were 
proteins loaded with the extraction buffer. It can be seen that extraction with 0.5% SDS 
buffer showed Ara h2 being extracted with very few other protein as compared to extraction 





Figure 19. SDS-PAGE analysis of different buffers used to extract protein. Lanes: (1) 
molecular marker (2) 8 M Urea (dialyzed, lyophilized, and re-dissolved protein powder) 
(3) 0.5% SDS (dialyzed, lyophilized, and re-dissolved protein powder) (4) protein in 8 M 
Urea buffer (5) protein in 0.5% SDS buffer.  
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In comparison, Method 1 protein extract was filtered using cheese cloth followed 
by ammonium sulfate precipitate twice, first going from 0 to 40% carrying the supernatant 
and then carrying the pellet in 40% to 70%. This part of the procedure was omitted in 
Method 2. Instead, the protein with extraction buffer was just subjected to centrifuge 
carrying the supernatant and passing it through syringe filter instead of cheese cloth. Next 
step in Method 1 requires dialyzing the pellet against TBS buffer so that it can be loaded 
onto Q Sepharose column. Method 2 also took the protein extract and was subjected to 
dialysis against 15 mM ammonium bicarbonate buffer. Protein from Method 1 was loaded 
onto the column after dialysis whereas protein that was on the lyophilizer was dissolved in 
TBS buffer and then loaded onto the Q Sepharose column.  
After loading protein onto the column, both were subjected to running gradient of 
TBS buffer containing 40 mM to 500 mM NaCl after 100 mL of TBS buffer with 40 mM 
NaCl was ran through to elute protein. Method 1 requires fractions that contain Ara h2 to 
be dialyzed against Tris buffer containing 3 M NaCl and then loaded onto a phenyl 
sepharose column for another column chromatography. Method 2 takes proteins that 
contain Ara h2 after doing coomassie G-250 dye bonding assay to find those fractions as 
seen in Figure 20 that shows which fractions were collected followed by SDS-PAGE 
analysis (Figure 21). It can be seen that Ara h2 (Figure 12, lane 4) along with other lower 
molecular weight proteins elute out of Q Sepharose column earlier followed by heavier 
proteins like Ara h1 (Figure 21, lane 11). The fractions containing Ara h2 are then subjected 
to centrifugal filter of 30K MWCO to eliminated proteins above 30K and thus purifying 
Ara h2. It can be noted that Method 2 can also be used to purify Ara h1 as well if needed. 
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A summary of the two-different methods is presented in a flowchart analysis in Figure 22 










































































































































Figure 21. SDS-PAGE of fractions collected after Q-Sepharose column chromatography 











Overall, the reaction of cross-linkers with Ara h2 was negative to visualize a dimer 
or oligomer formation on SDS-PAGE; however, a new purification method was developed 
that requires less steps and time to purify Ara h2 and Ara h1. Cross-linkers containing NHS 
esters could have reacted with Ara h2 protein; however, further characterization of cross-
linked product is needed to confirm. What was observed was that at higher concentration 
of cross-linkers like BS3 there was precipitation of protein out of the solution. This was 
seen for both Ara h2 and Ara h1 along with other proteins. The precipitation can be 
confirmed since the protein band intensity decreased as concentration of cross-linker was 
increased. Reaction with bifunctional thiol reactive maleimides was inconclusive 
according to SDS-PAGE gel. Reaction with EDC cross-linker was not visualized as well 
on the SDS-PAGE requiring further characterization. EDC reacts with a carboxylic acid 
group, which Ara h2 has plenty of as seen in Figure 9. The peptide that was used, TV1, 
could possibly be attached on Ara h2. As mentioned before, the proteins could have one of 
the cross-linkers attached without being visualized on the SDS-PAGE and that further tests 
are required to characterize the structures of protein comparing before and after addition 
of cross-linker.  
One of the possibility of not seeing cross-linking among Ara h2 protein could be 
the use of roasted peanuts. As stated in the introduction, roasted peanuts are subjective to 
the Maillard reaction which modifies lysine and arginine residues via glycosylation bond 
with sugars. Since Ara h2 protein was extracted from roasted peanut (most amount of 
protein extractable compared to raw protein), it is a possibility that Ara h2’s lysine sites 
could be glycosylated making them unreactive towards NHS esters.  Since there are only 
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3 lysine in Ara h2 (Figure 3), the reaction could be very slow requiring very precise energy 
and collision with cross-linker in the solution. Use of raw peanuts is a possibility in 
modifying Ara h2 since those proteins will not be glycosylated.  
If the cross-linkers were to have reacted with Ara h2, there would have been a dimer 
or trimer formation seen on the SDS-PAGE. This dimer or trimer would have been isolated 
and characterized followed by purification of the allergoid. The allergoid would then have 
been sent out for in vivo testing to see if it has an effect on allergenicity in animals allergic 
to peanuts. If the in vivo study would have been followed, the allergoid would have 






Dipeptidyl Peptidase-IV Inhibition for Treatment of Type 2 Diabetes 
Introduction 
Diabetes mellitus. Undoubtedly diabetes is one of the most severe disease in the 
human history. Diabetes has been found dating back around 1500 B.C. by the ancient 
Egyptians, who found effected people to urinate frequently and lose weight. The term 
diabetes mellitus was first coined by Greek physician Aretaeus who lived from about 80 to 
138 C.E. Since the first measurements of glucose in urine in 1776 till now, there have been 
major improvements in understanding and controlling diabetes.70 Diabetes mellitus is a 
disease where the blood glucose or blood sugar levels are too high. The homeostasis of 
glucose is disrupted because the body is not producing sufficient amounts of insulin or 
cannot properly use insulin. Glucose from the food is important to be transported from the 
blood to the inside of the cells to produce ATP. This is assisted by the hormone insulin 
which is produced by the organ pancreas. There are two types of diabetes mellitus; type 1 
diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), both based on the amount 
of insulin produced by a person. With T1DM, body does not make insulin and with T2DM, 
which is the more common type of diabetes, the body does not make or use insulin well 
enough. 
T2DM is one of the most important diseases of our time, with reported incidence 
increasing yearly among global population dramatically. It is projected that by 2025 there 
will be a 13.2 million increase in the number of people suffering from the disease 
specifically in the U.S.; with T2DM being the most prevalent and commonly seen in 90-
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95% of the cases. This disease represents to be a global epidemic problem increasing 
morbidity, mortality and cost of care as diabetes has also been strongly associated with 
cardiovascular and cerebrovascular diseases. Initially at an earlier stage slow advancing 
insulin resistance is seen, which later advances to glucose intolerance and finally T2DM 
occurs over several years.71  
According to the American Diabetes Association, 29.1 million Americans (9.3% of 
population) had diabetes in 2012 with 21.0 million diagnosed and 18.8 million 
undiagnosed. This is an increase of 1.0% from 25.8 million in 2010 to 29.1 million in 2012. 
The incidence of new diabetes cases was about the same in 2012 from 1.9 million in 2010 
to 1.7 million in 2012. However, the number of Americans age 20 and older with 
prediabetes went up from 79 million in 2010 to 86 million in 2012. Diabetes is also high 
in certain ethnicity as 7.6% are non-Hispanic whites, 9.0% Asian Americans, 12.8% 
Hispanics, 13.2% non-Hispanic blacks and 15.9% American Indians/Alaskan Natives. The 
breakdown among Asian American is as follows; 4.4% Chinese, 11.3% Filipinos, 13.0% 
for Asian Indians and 8.8% for other Asian Americans. The breakdown among Hispanic 
adults is 8.5% Central and South Americans, 9.3% Cubans, 13.9% Mexican Americans 
and 14.8% Puerto Ricans.72 
Diabetes is ranked number 7th as the leading cause of death in the U.S. in 2010, 
with 69,071 death certificates listing it as the underlying cause of death, and a total of 
234,051 death certificates listing diabetes as an underlying or contributing cause of death. 
It is mentioned that deaths by diabetes is underreported due to the fact that only 35% to 
40% of people with diabetes had it listed on their death certificate as the cause of death and 
that about 10% to 15% had it listed as the underlying cause of death.72 
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There are also two other categories called prediabetes and gestational diabetes. 
Prediabetes just means that you are at a borderline for T2DM and this can be prevented 
with proper exercise and diet. Gestational diabetes is when the blood sugar levels are high 
during pregnancy. About 7 out of 100 pregnant women in the U.S. get gestational diabetes 
and this is when a woman is pregnant for the first time. This increases the chances of 
developing T2DM later on and also increases in the child for obesity and T2DM. However, 
the focus of this study was on the control of T2DM since it is the most occurring type of 
diabetes. A simple blood test can show if you have diabetes which will be explained later 
on. Without enough insulin, the glucose from the food stays in the blood and over time can 
cause serious problems described hereafter. 
Important hormones of pancreas in maintaining homeostasis of blood glucose. 
Before dwelling in the symptoms of diabetes, it’s important to know the functions of 
pancreas and its secretion of important hormones for the homeostasis of glucose in the 
body. The pancreas secretes two important hormones, insulin and glucagon, along with 
digestive functions. There are other hormones secreted by the pancreas like amylin, 
somatostatin, and pancreatic polypeptide, however, their functions are not well known. The 
pancreas is composed of two major types of tissues; the acini and islets of Langerhans. The 
acini secrete digestive juices into the duodenum and the islets of Langerhans secrete insulin 
and glucagon directly into the blood. Insulin is released from the beta cells which make up 
the majority of cells (60% to 70%) in islets of Langerhans and glucagon is released from 
alpha cells which make up the second most abundant (25%) of islets of Langerhans.73  
Insulin is stimulated by many stimuli with glucose being one of them. Glucose 
enters the beta cells via the glucose transporter type 2 (GLUT-2) and it is phosphorylated 
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by the enzyme glucokinase which serves as the glucose sensor for the beta cells and triggers 
the release of insulin as the glucose exceeds about 5 mM concentration. Another important 
factor according to Tan74 is that orally administered glucose causes a greater increase in 
insulin than when it is administered via intravenous. The reason for this difference is due 
to increased production of incretin hormones such as glucagon-like peptide 1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide also called gastric inhibitory polypeptide 
(GIP) (discussed in greater detail below). These hormones are secreted by the 
gastrointestinal tract when food or glucose is orally consumed and causes direct activation 
of G-protein coupled receptors expressed on islet beta cells and thus indirectly increases 
insulin production. This is one of the ways to control insulin production and in turn 
controlling blood glucose levels.74,75  
Insulin is a polypeptide made of two peptide chains, A and B, linked together by 
disulfide bridges. It is synthesized as preproinsulin, which is then cleaved in the 
endoplasmic reticulum to form proinsulin, which is then self-cleaved in the Golgi apparatus 
to form insulin and C-peptide. Insulin causes the storage of excess nutrients while 
inhibiting mobilization of endogenous substrates like glycogen. Insulin mediates glucose 
entry into most cells, in particular the muscle (skeletal and cardiac) cells. The brain and red 
blood cells are exceptions in which glucose is imported via diffusion down a steep 
concentration gradient. Insulin also stimulates glycogen production from glucose in muscle 
and liver while inhibiting glycogen breakdown in the liver. In adipose tissues, insulin 
inhibits triglycerides from breaking down by suppressing hormone-sensitive lipase 
activity. This decrease in free fatty acid release from adipose tissues causes a decrease in 
beta oxidation by the liver and thus a decrease in the production of ketone bodies. It is also 
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commonly seen in patients having T1DM who produce no insulin where the ketone bodies 
are increased because free fatty acid release is increased causing diabetic ketoacidosis.74 
The other hormone released by the pancreas is Glucagon, which is a 29-amino acid 
long peptide produced from proglucagon. Glucagon has almost opposite affect than insulin 
in a sense that when blood glucose levels fall, glucagon helps to increase the blood glucose 
concentration by converting stored glycogen via glycogenolysis in the liver to glucose. 
Glucagon binds to the hepatic membrane receptor and causes a cascade of intracellular 
events via cyclic adenosine monophosphate (cAMP) as a second messenger, to regulate 
number of enzyme kinases or phosphatases. It is also important to note that patients with 
liver disease are hard to treat for hypoglycemia with glucagon. Another function of 
glucagon is the activation of myocardial adenylate cyclase which causes an increase in the 
cardiac output and should be monitored in T1DM.74  
The cascade of insulin resolved glucose clearing from the blood to the tissues is 
known as the insulin signal transduction pathway. The activation of insulin receptors by 
insulin causes phosphorylation events of many, if not all, downstream components. The 
insulin-stimulated phosphorylation of phosphatidyl inositol-3-kinase (PI3K) stimulates the 
phosphorylation of two downstream proteins—protein kinase C (PKC)-ζ and protein 
kinase B (Akt). Phosphorylated PKC-ζ and Akt initiate two separate pathway branches, 
both of which ultimately lead to the translocation of glucose transporter 4 (GLUT4) from 
the cytoplasm to the plasma membrane. Once at the plasma membrane, GLUT4 facilitates 




Importance of controlling symptoms related to diabetes mellitus. Diabetes is 
known to cause number of complications like hypoglycemia, hypertension, dyslipidemia, 
stroke, blindness/eye problems, kidney disease and amputations. The common symptoms 
of diabetes are polyuria, polydipsia, feeling very hungry even after having a meal, extreme 
fatigue, blurry vision, cuts and bruises that are slow to heal, weight loss even though you 
are eating more (T1DM) and tingling, pain, or numbness in the hands or feet (T2DM). 
These symptoms are easy to detect in T1DM but are so faint in T2DM that they are 
sometimes unnoticed. Thus, it is important to detect early and treat diabetes which can 
decrease the risk of developing the complications of diabetes. There are several ways to 
diagnose diabetes which should be done in a health care setting such as doctor’s office or 
at a certified lab that measures blood glucose levels.  
In 2011, about 282,000 patients who visited the emergency room and were adults 
aged 18 and older had hypoglycemia as the first-listed diagnosis and diabetes as another 
diagnosis.72 Hypoglycemia is a condition that is caused by a decrease in blood glucose 
levels of less than 70 mg/dL (normal <140 mg/dL). Some of the signs and symptoms of 
hypoglycemia include huger, nervousness, shakiness, perspiration, dizziness or light-
headedness, sleepiness and confusion. Hypoglycemia can be grouped into two broad 
categories; autonomic and neuroglycopenic. Autonomic consists of sweating, heart 
palpitations, shaking, dizziness, hunger, etc. and neuroglycopenic includes confusion, 
drowsiness, speech difficulty, odd behavior, incoordination, etc.77  
People with chronic kidney disease have a higher frequency of hypoglycemia than 
people with diabetes who do not have chronic kidney disease. Chronic kidney diseases 
affect how the drug is cleared and thus the drug’s half-life. It also decreases degradation of 
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insulin in peripheral tissues resulting in a lowered insulin requirements and thus having 
longer lasting effects of insulin in the body. As the body gets older, the kidney functions 
decrease and it can be concluded that elderly patients are at increased risk of hypoglycemia. 
Their kidneys are insufficient at drug clearance thus increasing drug interactions due to 
long lasting effect of drug in the body and decreased cognitive functioning. This leads to 
very important concern in elderly patient since hypoglycemia unawareness and 
deteriorated cognitive function are critical factors to be carefully considered in treating 
older patients.77 
In 2011, diabetes was listed as the primary cause of kidney failure in 44% of all 
new cases registered. There were 49,677 people who started treated for some sort of kidney 
failure due to diabetes alone. Another shocking number is in 2011, 228,924 people of all 
ages with kidney failure due to diabetes were living on chronic dialysis or with a kidney 
transplant. According to the Renal Data System between 1990 and 2006, there was an 
increase of about 9% per year in end stage renal disease (ESRD). The population sample 
was of Caucasian’s in the USA aged 20 to 49 years old with T1DM predominant diabetes 
type and almost the exclusive type. The patients developed ESRD as a result of having at 
least 15 years or sufficient duration of diabetes. Incident cases of ESRD attributed to 
diabetes numbered 3,359 in 1990, 3,972 in 1995, 4,287 in 200 and 4,600 in 2006.78  
Another complication associated with diabetes is hypertension. Hypertension is 
high blood pressure in the blood vessels that has a force greater than normal. Continues 
high pressure can strain the heart, damage the walls of the blood vessels, and increase risk 
of heart attack, stroke, kidney problems and death. From 2009 to 2012, adults of age 18 
years and older, 71% had blood pressure greater than or equal to 140/90 mmHg (normal 
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<120/80 mmHg) or used prescription medications to control high blood pressure.72 In fact, 
vascular complications are found to have an effect not only on the peripheral organs but 
also on cerebral circulation. The elasticity of smooth muscle cells is decreased with chronic 
hyperglycemia thus reducing the ability of blood vessels to maintain sufficient blood and 
nutrient supply to the brain tissue. Patients with T2DM and hypertension as a conjugate 
diagnosis showed a decreased in cortical gray matter thickness and cerebrovascular 
reactivity in a spatially overlapping region of the occipital lobe compared to healthy age-
matched controls with just hypertension. Impact of these regions have shown a decrease in 
cognitive thinking thus making prevention and control of diabetes an even more important 
factor.79 
Along with hypertension, dyslipidemia was diagnosed in 65% of patients with 
blood low density lipid (LDL) cholesterol greater than or equal to 100 mg/dL or used 
cholesterol-lowering medications who were 18 years and older from 2009 to 2012.72 
Normal level of LDL should be <100 mg/dL, (high density lipid) HDL should be <40 
mg/dL and triglycerides should be <150 mg/dL. Diabetic dyslipidemia is where the fasting 
and postprandial triglycerides are elevated, low HDL-cholesterol, elevated LDL-
cholesterol and the predominance of small dense LDL particles. This causes a 2 to 4 time 
increase risk of stroke and death from heart disease (increase in cardiovascular disease 
(CVD)) in patient with diabetes compared to non-diabetic patients. When insulin is 
produced in insufficient quantity, very low-density lipoprotein (VLDL) is increased as a 
main transporter of fasting triglycerides. Insulin suppresses lipolysis in adipose tissues by 
inhibiting the activity of hormone sensitive lipase, which catalyzes the mobilization of free 
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fatty acids from stored triglycerides, which act as substrates and regulatory factors for 
VLDL assembly and secretion.80  
Overall, insulin is involved at all stages of VLDL production and secretion. Also, 
in the liver, insulin inhibits the transcription of microsomal triglyceride transfer protein, 
which in turn transfers triglycerides to nascent apolipoprotein B (apoB), which is the 
predominant surface protein of VLDL. When insulin is insufficient, liver increases the 
production of free fatty acid for energy which leads to decreased degradation of apoB, thus 
causing an overproduction of VLDL. As these VLDL molecules increase, they cause a 
cascade of events that leads to reduced HDL and increased small dense LDL levels.80 
CVD due to dyslipidemia and thus the death rates related to CVD were increased 
by 1.7 times from 2003 to 2006 among adults aged 18 years or older with diagnosed 
diabetes than among adults without diagnosed diabetes. Under CVD falls heart attacks and 
stroke. In 2010, hospitalization rates for heart attack were 1.8 times and stroke 
hospitalization rates were 1.5 times higher among adults aged 20 years or older with 
diagnosed than among adults without diagnosed diabetes. People with diabetes also had 
blindness and eye problems. In 2005 to 2008, of adults with diabetes aged 40 years or older, 
4.2 million (28.5%) people had diabetes retinopathy, which is damage to the small blood 
vessels in the retina that may result in loss of vision.72 
Some of the pharmacotherapies for diabetes treatment include the following 
categories: sulfonylureas, meglitinides, biguanides thiazolidinediones, sodium-glucose 
cotransporter 2 (SGLT2) inhibitors, alpha-glucosidase inhibitor, glucagon-like peptide-1 
analogs and dipeptidyl peptidase-4 (DPP-IV) inhibitors. The main focus of this research 
69 
 
will be on the inhibition of DPP-IV enzyme to treat T2DM but before that it’s imperative 
to know the other ways of controlling diabetes. 
Sulfonylureas and meglitinides class of drugs. These class of drugs interact with 
the sulphonylurea receptor (SUR) 1 (an integral component of pancreatic KATP channels) 
and close the adenosine triphosphate-sensitive potassium (KATP) channels in the pancreas. 
The blocking of KATP channels causes voltage-dependent Ca2+ channels (VDCCs), eliciting 
Ca2+ influx and a rise in intracellular Ca2+ that stimulates exocytosis of the insulin-
containing secretory granules.81 The only problem with blocking the KATP channels and 
increasing insulin is that these channels are also present in the coronary vascular smooth 
muscle cells and cardiomyocytes, but here the SUR components are of the SUR 2A and 
SUR 2B subtypes, respectively. The normal function of these channels in the heart are for 
adaptation to stress and have a central role in the signaling cascades underlying myocardial 
ischemic preconditioning and the cardiac responses to systolic overload. Thus, stimulation 
of such reactions by blocking the KATP channels in the heart can cause a response of a 
failing heart and can result in increased cardiovascular death.82  
It has been shown that when sulfonylurea-induced and meglitinide-induced insulin 
secretion in pancreatic beta cells exposed chronically, there is reduced insulin content and 
a reduced number of functional KATP channels on the plasma membrane, as well as 
accelerated apoptotic beta cell death. These two groups of drugs thus might not be as 
effective when used over time as it can cause impaired acute inusinotropic action of these 
agents.81  Currently there are 3rd generation sulfonylureas and several meglitinide class of 
drugs available that are approved by the FDA. 
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Biguanides class of drugs. This class refers to the group of drugs that control blood 
glucose level by decreasing amount of blood sugar produced by the liver, decreasing 
amount of sugar absorbed by the intestines and restoring body’s sensitivity to insulin. There 
is only one drug approved in this class which is metformin. Metformin is used primarily to 
treat T2DM but can be used to treat T1DM in combination with other therapeutics like 
insulin. Metformin decreases blood glucose levels by routes other than pancreatic 
mechanisms. Metformin increases body’s sensitivity to insulin and decreases rate of 
gluconeogenesis and small effect on glycogenolysis which in turn reduces the amount of 
blood glucose in the body helping control diabetes. Metformin is known to activate enzyme 
adenosine monophosphate kinase (AMPK) which inhibits key enzymes involved in 
gluconeogenesis and glycogen synthesis in the liver while also stimulating insulin 
signaling and glucose uptake by transporters in muscles. Metformin usually does not cause 
hypoglycemia which makes this class of drug a good choice. Metformin can cause serious 
side effect of lactic acidosis which is known to cause dizziness, severe drowsiness, muscle 
pain, tiredness, and other systemic symptoms, however, data has shown that these adverse 
effects are minute compared to the positive effects of metformin thus it is rarely 
discontinued from a patient’s medication regimen.83  
SGLT2 inhibitor class of drugs. Another class of prescription for controlling 
diabetes is SGLT2 inhibitors. SGLT is known to reabsorb glucose in the kidney and thus 
inhibiting it leads to excretion of glucose in the urine, hence decreasing plasma glucose 
level helping control diabetes. There are six active variants from SGLT1 to SGLT6, 
however, two types, SGLT1 and SGLT2, with SGLT1 (10% glucose reabsorption in 
kidneys) predominately expressed in intestine, kidney, heart, and skeletal muscle, and 
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SGLT2 (90% glucose reabsorption in kidneys) is exclusively expressed in kidney.84,85 
Under normal physiological conditions, 180 g of glucose is filtered through the kidneys 
daily and all of it is reabsorbed into the circulation by SGLT’s. SGLT transport sodium 
and glucose into the cells using Na+/K+ ATPase pumps followed by glucose being further 
passively transported into the interstitium by GLUT-2.84 Inhibition of SGLT2 improves 
hyperglycemia along with caloric and weight loss, small decreases in blood pressure and 
key property of low incidence of hypoglycemia due to insulin-independent mechanism of 
action. There are side effects like increased urinary and genital tract infections, diabetic 
ketoacidosis, skeletal effects (disruption of homeostasis of calcium and phosphorus), and 
some excess of bladder cancers seen exclusively with treatment using dapagliflozin.85 
Currently three compounds are approved for use which are dapagliflozin, canagliflozin, 
and empagliflozin.   
Thiazolidinediones class of drugs. The thiazolidinediones are peroxisome 
proliferators-activated receptor γ (PPAR-γ) agonists that alter the transcription of genes 
influencing carbohydrate and lipid metabolism. Patients who are at the risk of prediabetes 
can take thiazolidinediones to slow down the development of T2DM and patients who are 
diagnosed with T2DM can take thiazolidinediones to improve glycemic control. However, 
the use of thiazolidinediones is advised as a cautionary since the side effects are great which 
include body-weight gain, congestive heart failure, bone fractures and possibly bladder 
cancer. This led to warnings and eventually restrictions on the use of rosiglitazone in the 
U.S. by the FDA.86 Some of the members of thiazolidinediones include rosiglitazone, 
pioglitazone, lobeglitazone and troglitazone. 
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Alpha-glucosidase inhibitor class of drugs. Alpha-glucosidase inhibitors are 
effective against T2DM by controlling the post-prandial hyperglycemia. The enzyme 
responsible for absorbing the glucose in the intestine is alpha-glucosidase. This enzyme is 
a typical exo-type glycosidase enzyme that catalyzes the releases of alpha-glucosides from 
the non-reducing end of carbohydrates. It’s one of the key enzyme involved in absorbing 
glucose in the intestine after a meal. So, by inhibiting alpha-glucosidase, glucose can be 
reduced and thus can be effective in the treatment and management of hyperglycemia and 
hyperlipidemia. However, alpha-glucosidase inhibitors are known to cause various side 
effects, such as flatulence, diarrhea, and abdominal discomfort.87 Some of the drugs under 
this class are miglitol, acarbose and voglibose. 
GLP-1 analogs class of drugs. GLP-1 analogs are another possibility of treatment 
of T2DM since in vitro and animal studies have reported that GLP-1 is associated with 
multiple positive effects on pancreatic beta cells. It has also been reported that GLP-1 
regulates the expression of beta cell specific genes, regulates beta cell mass by inhibiting 
beta cell apoptosis and preventing beta cell glucolipotoxicity thus improved beta cell 
function.88 The incretins are also responsible for improving the heart and endothelium. 
Incretins decrease CV risk markers, infarct size, atherosclerosis, endothelial 
dysfunction/inflammation and endoplasmic reticulum (ER) stress.89 They also signal the 
brain to decrease food intake and increase cognitive function. Incretins are also helpful in 
increasing bone calcium levels and increasing glucose uptake in muscle cells indirectly. 
They are also shown to decrease gastric emptying which can help keep blood glucose levels 
from spiking rapidly causing hyperglycemia.90 
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Since GLP-1 plays an important physiological role in the body to control 
hyperglycemia along with other actives, it was a good pharmaceutical candidate to create 
analogs that mimicked GLP-1 peptide. Usually, GLP-1 peptide along with GIP is 
inactivated in T2DM by DPP-IV enzyme (discussed in greater detail below) making them 
useless in maintaining blood glucose homeostasis. These are naturally occurring hormones 
that are secreted in response to glucose ingested after a meal. These hormones are 
responsible for the incretin effect with more insulin secretion when ingested rather than 
taken intravenously. Some of the approved analogs for GLP-1 agonists are exenatide, 
liraglutide, lixisenatide, albiglutide and taspoglutide.  
Recent research depicts the details of the pathophysiology of the disease showing 
that there is an intricate interaction of hormonal (hormones of the pancreas) and neural 
stimuli which are involved in the regulation of plasma glucose and maintaining 
homeostasis.75 With the development of the enteroendocrine hormone equivalents and 
other compounds, which raise the concentration of these incretin hormones by delaying 
their degradation or by binding to their receptors, seem to aid in achieving a balance for 
the glycemic control.91 
These incretin hormones are deactivated by DPP-IV in the body. The rapid 
degeneration of GLP-1 by DPP-IV enzyme dramatically reduced its action making it less 
effective. With advance in research there has been two ways found to work with this 
problem. One is the development of a mimic of the incretin GLP-1 (discussed above) 
resistant from degradation by DPP-IV enzyme and second is the development of the DPP-
IV inhibitor (discussed next).75,92  
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DPP-IV enzyme inhibitor class of drugs. DPP-IV, EC 3.4.14.5, is an enzyme first 
described in 1967 as multifunctional membrane-anchored serine ectopeptidase belonging 
to the α,β-hydrolases (family S9B) and sequentially related to prolyl oligopeptidase (POP). 
The human 110 KDa DPP-IV is a 766-amino acid transmembrane glycoprotein consisting 
of mainly three parts: a cytoplasmic tail (residues 1-6), a transmembrane region (residues 
7-28) and an extracellular part (29-766). It is the extracellular region that is responsible for 
cleaving incretin hormones. Specifically, it is residues 508 to 766 that have a catalytic triad 
Ser630-Asp708-His740 and α/β-hydrolase fold and other eight-bladed β-propeller chain 
(residues 56-497) which also contributes to the inhibitor binding site. DPP-IV is secreted 
as a monomer but forms a dimer which is responsible for the proteolytic activity as seen in 
Figure 23 using computational modeling. DPP-IV cleaves peptide/substrate after the 2nd 
amino acid from the N-terminal end, specifically if the 2nd amino acid is alanine (like in 
GLP-1) or proline.90 The catalytic site lies in a large cavity between the two extracellular 







Figure 23. Molecular modeling of DPP-IV enzyme that is observed as a homodimer. Image 




DPP-IV inhibition prevents the inactivation of GLP-1, which increases levels of 
active GLP-1. As mentioned above, this effect increases insulin secretion and reduces 
glucagon secretion, thereby lowering blood glucose levels92 It has been estimated that 
incretin hormones increase insulin response by 66% after an oral glucose administration96 
GLP-1 is a 36-amino-acid peptide produced by the L cells, which are localized 
predominantly in the lower part of the small intestine. In GLP-1 secretion, which is released 
minutes after meal ingestion; fats, carbohydrates and proteins all alike have the same 
stimulator effect. GIP is a 42—amino-acid peptide produced mainly by the K cells, which 
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are located mainly in the duodenum. GIP is stimulated by fat and carbohydrates, whereas 
protein does not stimulate GIP as much.90,97  
Both GLP-1 and GIP are inactivated minutes after secretion (half-life in the order 
of 1 to 2 minutes) by DPP-IV. The use of DPP-IV inhibitors like sitagliptin and vildagliptin 
have clinically proven to significantly reduce HbA1c and offer many potential advantages 
over existing therapies which includes a lower risk of hyperglycemia, no weight gain along 
with no problems of gastrointestinal intolerance.75 In some of the animal studies, 
administration of DPP-IV inhibitors depicted a long life of up to 5 hours and an inhibition 
of more than 90% of plasma DPP-IV. When tested on T2DM patients, DPP-IV inhibitors 
showed a potent and long-lasting inhibition soon after its intake. Some other studies 
experimented with sitagliptin or vildagliptin also showed results depicting a significant 
increase of GLP-1 plasma levels.91 It has been shown that inhibition of DPP-IV increases 
the prandial levels of active GLP-1 approximately three-fold, from about 5-6 pmol/L to 15-
20 pmol/L.71  
When preclinical studies were administered using DPP-IV inhibitors, selective 
inhibition of DPP-IV was acceptable at the safety and tolerability criteria as compared to 
two other human dipeptidyl-peptidases DPP8 and DPP9 which belong to the same family 
as DPP-IV (post-proline serine peptidases). A study by Lankas et al.98 showed that both 
DPP8 and DPP9 are very weak inhibitors with data showing very low affinity as compared 
to DPP-IV, which displayed highest selectivity. Acute toxicity in rodents was reported with 
inhibition of enzymes DPP8 and DPP9 so in order for a compound to be an effective DPP-
IV inhibitor, the compound must show low affinity towards DPP8 and DPP9 and high 
77 
 
affinity towards DPP-IV. Thus, a lack of DPP8 and DPP9 inhibitory activity should be 
absent for the development of DPP-IV as an effective and safe antidiabetic therapy.75,99 
DPP-IV is also known as the T-cell antigen CD26, and is a cell-surface protease 
localized in numerous sites, including the kidney and intestinal brush-border membranes 
as well as on hepatocytes. DPP-IV is also found throughout the entire vascular bed, located 
on endothelial cells as well as in a soluble form in plasma.100 It is also widely distributed 
in kidney, liver, intestine, spleen, adrenal glands, lymphocytes, endothelial cells and 
placenta.93 Not only is DPP-IV used to cleave integrins, but it is also used to metabolize 
neuropeptide Y, peptide YY, gastrin-releasing polypeptide, pituitary adenylate-cyclase-
activating polypeptide, insulin-like growth factor-1, substance P and various chemokines. 
Metabolism and activation of peptide YY and neuropeptide Y which are involved in GI 
functions and regulation of food intake and obesity can be associated to the contributing 
factors of T2DM.75 The following activities of DPP-IV show that it is involved in other 
homeostatic mechanisms like neurogenic inflammation, blood pressure and the immune 
system.90  
The available FDA approved drugs for inhibiting DPP-IV enzyme are as follows; 
sitagliptin, vildagliptin, saxagliptin, alogliptin and linagliptin. Sitagliptin was used as a 
control in our research, which is sold as the brand name Januvia. Sitagliptin phosphate 
monohydrate is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-
trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-
a]pyrazine phosphate (1:1) monohydrate [C16H15F6N5O•H3PO4•H2O] with the R 
enantiomer being the active form of Januvia. Pharmacophore of sitagliptin is the 3-
(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4.3-a]pyrazine as shown in Figure 24 
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labeled sitagliptin binding region (SBR) with DPP-IV enzyme. There are two other 
pharmacophore sites on sitagliptin that are labeled common binding region (CBR) with 
DPP-IV enzyme. The amino acids associated with SBR are serine (S), phenylalanine (F), 
and arginine (R) at positions, 209, 357, and 358, respectively. The serine and arginine are 
both donating hydrogens to trifluromethyl and triazole, respectively. The phenylalanine is 
involved in pi-pi interactions with the aromatic ring. The other amino acids involved are 
glutamic acids (E) at position 205 and 206 and tyrosine (Y), valine (V), tryptophan (W), 
tyrosine (Y), aspartic acid (D) and tyrosine (Y) at positions 631, 656, 659, 662, 663 and 
666, respectively, on DPP-IV enzyme (Figure 24).101 
Based on current literature and structural requirements for a compound to be a DPP-
IV inhibitor, we were able to synthesize a lead compound that showed inhibitory activity. 
This lead compound was further used to build a library of DPP-IV inhibitors via structural 








Figure 24. Molecular modeling of DPP-IV enzyme in complex with inibitors. (a) β-amino 






Characteristic of DPP-IV Inhibitors and their Validation via In Vitro DPP-IV 
Enzymatic Assay 
Novel Compounds Containing Cyanopyrrolidine and β-amino Alcohols Scaffolds 
Inhibitors of DPP-IV required specific structural groups to prevent the function of 
this enzyme. Cyanopyrrolidinyl β-amino alcohols are novel scaffolds with potential for a 
wide array of pharmacological properties. These scaffolds were selectively accessed from 
simple and inexpensive commercially available chemicals in few synthetic steps with 
minimal purification. A 36-compound library of these scaffolds were provided to be 
examined as DPP-IV inhibitors.102  
Cyanopyrrolidines are molecular scaffolds that are highly recurrent among natural 
products and commercial drugs. The scaffold has shown affinity to dipeptidyl peptidases 
as a proline mimetic group and it has been hypothesized that the activity arises from a 
transient covalent interaction of the nitrile with S630 that triggers a slow dissociation from 
the enzyme. Thus, most of the most potent DPP-IV inhibitors contain this scaffold 
(vinagliptin, saxagliptin, vildagliptin). Cyanopyrrolidines can be easily obtained from 
naturally available proline and many synthetic approaches are available. However, despite 
the diversity of methods many lack scalability and reproducibility.102 
β-Amino alcohols are an important class of compounds in medicinal chemistry and 
drug discovery due to their high occurrence in commercially available drugs. They often 
behave as β-adrenergic blockers, widely used in the management of cardiovascular 
disorders, including hypertension, anginapectoris, cardiac arrhythmias, and other disorders 
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related to the sympathetic nervous system. Amino alcohols have also been used as protein 
kinase C inhibitors, glycosidase inhibitor and antimalarial agents. Among commercial 
drugs, this scaffold is present in Oxycontin, Coreg, and Toprol-XL. Other pharmaceutical 
drugs such as Zyvox and Skelaxin feature oxazolidones that can be formed through amino 
alcohol precursors. Moreover, these can be used as chemical synthons for the synthesis of 
more complex heterocyclic scaffolds. Thus, a novel family of inhibitors that shares the 
cyanopyrrolidine and β-amino alcohol scaffolds towards more potent and selective diabetes 
therapeutics were created and tested.102  
Research Design and Methods 
General Method A: Synthesis of mono-alkylated amino alcohols. In a 20 mL 
vial at room temp., epoxide (1.0 mmol, 1.0 equiv.) and amine (1.5 mmol, 1.5 equiv.) were 
added to 6.7 mL of DMF. The reaction was stirred at 60 °C for 12 h at which point the rxn 
mixture received deionized water (50 equiv.). The reaction was allowed to stir at 60 °C for 
an additional 12 h. The resulting crude was stripped of solvent and the residue loaded 
directly onto a silica gel column for purification.102 
General Method B. Synthesis of double-alkylated amino alcohols. In a 20 mL 
vial at room temp., epoxide (2.0 mmol, 2.0 equiv.) and amine (1.0 mmol, 1.0 equiv.) were 
added to 5 mL of deionized water. The reaction was stirred at room temp. for 12 h. The 
resulting crude was stripped of water and the residue loaded directly onto a silica gel 
column for purification.102 
Compounds. (2S)-1-((2-hydroxy-2-phenylethyl)glycyl)pyrrolidine-2-carbonitrile 






































carbonitrile (14aa): and (2S)-1-((3-(furan-2-ylmethoxy)-2-
hydroxypropyl)glycyl)pyrrolidine-2-carbonitrile (15aa).  
In vitro assay. The enzymatic inhibition of DPP-IV was measured in vitro by the 
endpoint fluorometric assay using substrate Gly-Pro-AMC (MW: 329.4). The enzyme 
cleaves the bond between Pro-AMC thus releasing the fluorescent aminomethylcoumarin 
(AMC) resulting in an increase in fluorescence intensity. The inhibitors, DPP-IV enzyme 
and substrate were dissolved in the 100 mM HEPES buffer (pH 7.5, 0.1 mg/ml BSA). 
Inhibitor stock concentration was dissolved in 100% DMSO followed by working serial 
dilution starting at 1% DMSO. The final concentrations of enzyme and substrate used were 
0.003 ng/µL and 50 µM, respectively.  
The assay was performed in an 384-Well plate (from BD Falcon, catalog # 353232, 
well 120 µL assay plate white, standard surface, nonsterile) with final volume of 100 µL 
in all wells. All samples were assayed in triplicates. A background well was created with 
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10 µL of Gly-Pro-AMC (from MP Biomedicals, LLC, catalog # AMC039) substrate plus 
90 µL buffer; a 100% activity well was created with 10 µL of DPP-IV enzyme (from 
Sigma-Aldrich, Inc., catalog # D7052) and 10 µL of Gly-Pro-AMC substrate plus 80 µL 
buffer; and inhibitor wells were created with 10 µL of DPP-IV enzyme, 10 µL of inhibitor 
and 10 µL Gly-Pro-AMC substrate plus 70 µL buffer. The order of the addition to the well 
was buffer, enzyme, inhibitor and finally the substrate to initiate the reaction. The plate 
was covered and centrifuged for 30 seconds at 800xg followed by incubation for 30 mins 
at 37° C. The fluorescence was the measured on the SpectraMax M5 with excitation 
wavelength of 360 nm and emission wavelength of 460 nm with an auto cut-off wavelength 
setting on the instrument at 37° C. IC50 values were analyzed using Graphpad Prism 6 by 
a fit of reaction rates to a four-parameter Hill equation by nonlinear regression. Equation 
used to calculate IC50:  
Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)) 
Where IC50 is the concentration (same unit as X) of inhibitor that gives a response half 
way between Bottom and Top (plateaus in the units of the Y). HillSlope describes the 
steepness of the family of curves. A HillSlope of -1.0 was used. 
Results and Discussion 
Two different series were created, cyano (mono-alkylated (aa) and double-
alkylated (ba)) and descyano (mono-alkylated (ab) and double-alkylated (bb)). Table 2 
shows series 1 to 9 and Table 3 shows series 10 to 15 of DPP-IV inhibitor. It can be seen 
from series 10 to 15 that ab, ba, and bb were not synthesized as the Structural Activity 
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Relationship (SAR) from series 1 to 10 showed no activity for compounds containing these 
characteristics.  
It was anticipated that series aa would establish the baseline activity for these 
inhibitors and that is what was observed as aromatic cyanopyrrolidinyl amino alcohols 
demonstrated to have significant potency (IC50 under 0.2 uM). All mono-alkylated 
compounds with cyano group aa showed greater activity than all double-alkylated bb 
series. It was observed that analogue 1aa (42 nM) (Figure 25) had significant more 
inhibition against DPP-IV than the other substituted aromatic analogues 
(2aa, 3aa and 4aa) (Figure 26) where the epoxide used was styrene oxide. Moreover, from 
those the p-fluorophenyl analogue 2aa (6511 nM) surprisingly displayed much lower 
inhibition followed by p-chlorophenyl 3aa (123.5 nM), then p-bromophenyl 4aa (121.6 
nM) and highest activity when there was no substitution 1aa (42.19 nM). What was 
surprising was 4ba (129.6 nM) showed similar IC50 to 4aa analog along with some activity 
in descyano mono-alkylated 4ab (1299 nM) and no activity for descyano double-alkylated 
4bb (Figure 27). Compounds in entry 4 containing bromine on the aromatic were the only 
series that showed activity in ba and ab series as all other compounds containing ba and 
ab series showed >10K nM IC50.  
Phenylgylcidyl ethers were used to react with amino alcohol series and it was found 
that the respective cyanopyrrolidine amino alcohols were obtained in great yields and as 
single isomers (Table 1, Entry 5). The resulting amino alcohols were obtained as mixtures 
of diastereomers at the alcohol and cyano centers, but due to their remote relationship, they 
are seen as one isomer by NMR spectroscopy. Despite the remoteness between the chiral 
centers on the proposed target, we anticipated that we might need to construct this scaffold 
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as a single diastereomer to validate the effect of the remote chiral center. Thus, (S)-
phenylglycidyl ether was reacted with the amine series to get products (Table 1, Entry 6). 
The scaffold remote relationship between its chiral centers suggested that as a mixture of 
diastereomers, the scaffold inhibition would be potentially comparable. We corroborated 
this hypothesis as we found that the inhibitory activity of 5aa (91.02 nM) (mixture of 
diastereomers) (Figure 28) was very similar to the enantiopure amino alcohol 6aa (81.72 
nM) (Figure 29). The introduction of phenoxy ethers is known to enhance activity among 
several β-adrenergic blockers 103. Consequently, we found the SAR of phenoxy in series 
5aa and 6aa, o-methylphenoxy in 7aa (98.93 nM) (Figure 30), benzyloxy in 8aa (80.24 
nM) (Figure 31) and p-methoxy in 9aa (74.32 nM) (Figure 32) to have similar inhibitory 
properties as to the previous analogues but failed to improve 1aa activity.  
Based on the current SAR data found, we envisioned that introducing fluorine 
atoms on the phenoxy group might further increase the inhibitory properties. We found 
that p-fluorophenoxy 10aa (112.6 nM) had comparable activity. Moreover, 4,5-
difluorophenoxy 11aa (77.96 nM) proved to be more active (analogues to SAR from 
reported studies), but 4,5,6-trifluorophenoxy 12aa (141.19 nM) proved to decrease the 
inhibitory activity. Figure 33 shows the dose-response curve comparing the number and 
placement of fluorine on the phenoxy group. Further assessment of the SAR demonstrated 
that naphthyl cyanopyrrolidinyl amino alcohol 13aa (100.6 nM) is comparably active. 
Interestingly, removing the oxygen from the benzyloxy analogue 14aa (2680 nM) fully 
drops DPP-IV activity. Low activity from heterocyclic analogue 15aa (>10K nM) further 
proved the need for a more lipophilic side chain.102 Figure 34 displays the dose-response 
curve comparing analogous compounds 13aa, 14aa and 15aa.  
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It was found that the remaining analogues had significantly lower inhibitory 
activity. Moreover, Series ab/bb also failed at providing significant activity against DPP-
IV. The SAR data from this preliminary biochemical study shows that analogue 1aa is the 
most active (42 nm), and analogues that introduce complexity around the phenyl ring have 
comparable inhibitory properties. It has been demonstrated that the monoalkylated scaffold 
is by far the most active scaffold. Despite reported evidence of a potential decomposition 
pathway through an acid-catalyzed intramolecular cyclization, stability studies displayed 
complete structural stability for the inhibitor against analogous conditions. This study also 
has shown that fluorine incorporation can improve activity, but does not play a significant 
role as seen in other DPP-IV inhibitors.102 
Conclusion 
Novel cyanopyrrolidinyl β-amino alcohols were derived and successfully tested in 
vitro against DPP-IV enzyme. All of the mono-alkylated amino alcohols showed greater 
activity than all of the double-alkylated amino alcohols against DPP-IV enzyme. It was 
also shown that all compounds that contained the cyano group on the pyrrolidinyl amine 
showed greater activity than compounds without the cyano group. Compounds containing 
phenyl glycidyl ethers showed greater activity than styrene oxides. When styrene oxide 
was substituted with halogens, bromine showed activity greater than chlorine followed by 
fluorine; however, no substitution showed the greatest activity. When fluorine was 
substituted on the phenyl glycidyl ether, it was found that para substitution was favored 
followed by meta which was better than no substitution. It can also be concluded from the 




Since these novel molecules contain the β-amino alcohols, the next step is to test 
them against β-adrenergic receptors as potential β-blockers which would make these 
compounds a dual acting drug that would be beneficial in maintenance of diabetes and 
hypertension. Also, since literature has shown toxicity to the animal when enzymes DPP8 
and 9 were inhibited along with DPP-IV, it is important for these compounds to be tested 
against DPP8 and 9 enzymes as it will help in synthesizing a more potent second-
generation library of DPP-IV inhibitors. Not only is activity against DPP8 and 9 important 
for second-generation library, but it is important so that these molecules can be further 




















































































































































































































































































































































































































































































































































































































































































































































































 Problem of peanut allergenicity was investigated since the rate of prevalence and 
burden on the western world has increased in recent decade. We looked to find a solution 
that would alleviate majority of people allergic to peanuts in the most efficient way. Since 
majority of allergic reactions are due to macromolecule protein, we looked to manipulate 
proteins of peanut, specifically Ara h2, since it has been shown in literature that IgE to Ara 
h2 has been found in majority of people allergic to peanut. Before we could manipulate 
Ara h2, we needed great amounts of protein to work with in an efficient manner. Thus, we 
were able to come up with a novel purification method that allowed us to purify Ara h2 
efficiently.  
 After having sufficient amount of Ara h2 to work with, we had the task of 
modifying the protein without completely destroying it. We looked to mask various 
epitopes of Ara h2 by cross-linking the proteins together using various cross-linkers that 
included BS3, DST, EDC, Sulfo-EGS and BM[PEG]3. These cross-linkers were utilized 
according to literature and cross-linked with Ara h2 at various conditions that manipulated 
temperature, pH and native/reduced form of protein. After cross-linking, protein was 
visualized on SDS-PAGE gels for visual confirmation of polymerization of the protein, 
which was negative. On various cross-linkers, as concentration of cross-linker was 
increased, there was disappearance of protein as seen on the lanes of SDS-PAGE gel. This 
102 
 
could have been due to the insolubility of the newly formed cross-linked product that was 
not able to dissolve in sample buffer and thus unable to be visualized on the SDS-PAGE.  
 Further characterizations are required to confirm if Ara h2 had not indeed been 
cross-linked with various cross-linkers. One method is to determine the protein 
concentration of Ara h2 in control sample compared to various concentrations of cross-
linker and protein samples combined. This can be done using ELISA that includes IgG 
antibodies specific to Ara h2 to see how the concentration has decreased as concentration 
of cross-linker has increased. Another approach is to determine changes in the secondary 
structure of Ara h2 using CD, however, with caution since Ara h2 exists as two different 
isomers. If there is indeed a cross-linking between molecules of Ara h2, we should be able 
to confirm this change in mass using mass spectrometry. Finally, to confirm a decrease in 
allergenicity of Ara h2, ELISA or Western blot can be utilized with IgE antibodies since 
these antibodies are responsible for causing allergic reaction in the body.  
 Overall, various cross-linkers were tested, however, more empirical proof is 
required to confirm a change in structure of Ara h2 along with confirmation of decreased 
binding to IgE specific to Ara h2.     
Diabetes Mellitus 
 Diabetes is an increasing problem everywhere in the world. The number of newly 
diagnosed cases of diabetes has been increasing, however, there is also an increase in new 
drugs that are either in clinical trials or have been recently approved for treatment of 
diabetes. We decided to look into treating diabetes, specifically type 2 diabetes by the 
mechanism of inhibiting enzyme DPP-IV in the body. This enzyme is known to cleave 
103 
 
incretin hormones in the body that are responsible for aiding in decreasing blood glucose 
levels. It has been shown in literature that by inhibiting this enzyme in the body, it is 
possible to control T2DM. However, we were interested in not just controlling diabetes but 
to help people who are also diagnosed with hypertension associated with diabetes. We 
wanted to synthesize novel compounds that would target DPP-IV enzyme and β-adrenergic 
receptors as one compound containing two different pharmacophores targeting two 
different protein structures in the body. 
 We were able to incorporate cyanopyrrolidine and β-Amino alcohol scaffolds to 
make a novel 36-compound library. These compounds were successful tested for SAR 
activity against DPP-IV enzyme in vitro assays. A series of characteristics were determined 
that will now allow for synthesis of second generation library. We are in the 
implementation of next step which is taking the most potent DPP-IV inhibitor compounds 
and testing them against DPP8 and DPP9. We are also in the process of testing the most 
potent compounds against CHO cell lines that express β-adrenergic activity in vivo assay. 
This data will allow us to move into in vivo studies that would test for blood glucose levels 
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